var title_f21_21_21840="Piebaldism - trunk and extremities";
var content_f21_21_21840=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F71514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F71514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Piebaldism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple depigmented patches are present on the trunk and legs in this patient with piebaldism.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_21_21840=[""].join("\n");
var outline_f21_21_21840=null;
var title_f21_21_21841="Evaluation early contractures";
var content_f21_21_21841=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 568px\">",
"   <div class=\"ttl\">",
"    Evaluation of a child with early contractures, with or with without mild muscle weakness, and no definite cardiac or respiratory abnormalities",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 548px; height: 592px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Algorithm for the evaluation of a sporadic patient with early contractures - with or without mild muscle weakness - and no definite cardiac abnormalities.",
"    </p>",
"    <div class=\"footnotes\">",
"     <p>",
"      AD: autosomal dominant; AR: autosomal recessive; EDMD: Emery-Dreifuss muscular dystrophy; CM: congenital myopathy; CMD: congenital muscular dystrophy; IHC: immunohistochemistry; LMNA: lamin A/C; RSS rigid spine syndrome; X: X-chromosome linked.",
"      <br>",
"       <br>",
"        * It is possible to skip \"IHC for emerin\" and go directly to \"X-EDMD (emerin) gene mutations\" in centers where genetic testing is easily available. For girls, both steps should be skipped, since X-chromosome linked EDMD is not a likely consideration, going directly to LMNA gene mutation testing.",
"       </br>",
"      </br>",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Deymeer F. Emery-Dreifuss muscular dystrophy. In: Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach, Jones HR, De Vivo DC, Darras BT (Eds). Butterworth Heinemann, Philadelphia 2003. p.753. Copyright &copy;2003 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_21_21841=[""].join("\n");
var outline_f21_21_21841=null;
var title_f21_21_21842="Molluscum contagiosum pediatric genital";
var content_f21_21_21842=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Molluscum contagiosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple umbilicated small papules are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_21_21842=[""].join("\n");
var outline_f21_21_21842=null;
var title_f21_21_21843="Positions of anterior dislocations of the shoulder";
var content_f21_21_21843=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F64651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F64651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Positions of anterior dislocations of the shoulder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 482px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_21_21843=[""].join("\n");
var outline_f21_21_21843=null;
var title_f21_21_21844="Triquetral fracture difficulty";
var content_f21_21_21844=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F59010%7EEM%2F67772%7EEM%2F81364&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F59010%7EEM%2F67772%7EEM%2F81364&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Triquetral fracture difficulty",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The difficulty of identifying a fracture of the triquetrum using standard anterior-posterior radiographs of the wrist is apparent in this image, in which the superimposed shadow of the pisiform obscures the fracture. Note the small density (arrow) near the ulnar styloid which could represent a fracture fragment or a possible concomitant lunate fracture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Triquetral fracture on lateral plain x-ray",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this lateral radiograph of the wrist, a fracture of the dorsal surface of the triquetrum is apparent (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Triquetral fracture on oblique x-ray",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this oblique radiograph of the wrist, the shadow of the pisiform does not overlap the triquetral fracture (arrow). Note the small fragment near the ulnar styloid. In this view the remainder of the wrist bones appear normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_21_21844=[""].join("\n");
var outline_f21_21_21844=null;
var title_f21_21_21845="Bullous lupus erythematosus chest";
var content_f21_21_21845=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F86216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F86216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Bullous systemic lupus erythematosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple blisters and erosions&nbsp;are present on the chest of this patient with bullous systemic lupus erythematosus.",
"    <br>",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Courtesy of Samuel L Moschella, MD.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_21_21845=[""].join("\n");
var outline_f21_21_21845=null;
var title_f21_21_21846="Impetigo";
var content_f21_21_21846=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Impetigo",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/21/21846/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/21/21846/contributors\">",
"     Larry M Baddour, MD, FIDSA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/21/21846/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/21/21846/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/21/21846/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/21/21846/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/21/21846/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/21/21846/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impetigo is a contagious superficial bacterial infection observed most frequently in children. It may be classified as primary impetigo (direct bacterial invasion of previously normal skin) or secondary impetigo (infection at sites of minor skin trauma such as abrasions, minor trauma, and insect bites, or underlying conditions such as eczema). Pyoderma and impetigo contagiosa are sometimes used as synonyms for impetigo.",
"   </p>",
"   <p>",
"    Impetigo is most frequently observed in children ages two to five years, although older children and adults may also be affected. The infection usually occurs in warm, humid conditions and is easily spread among individuals in close contact; risk factors include poverty, crowding, poor hygiene, and underlying scabies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21846/abstract/1\">",
"     1",
"    </a>",
"    ]. Carriage of group A streptococcus (GAS) and Staphylococcus aureus predisposes to subsequent impetigo [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21846/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variants of impetigo include non-bullous impetigo, bullous impetigo, and ecthyma. Poststreptococcal glomerulonephritis and rheumatic fever following impetigo have also been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Non-bullous impetigo",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-bullous impetigo is the most common form of impetigo. Lesions begin as papules that progress to vesicles surrounded by erythema. Subsequently they become pustules that enlarge and break down to form thick, adherent crusts with a characteristic golden appearance; this evolution usually occurs over about one week (",
"    <a class=\"graphic graphic_picture graphicRef75066 \" href=\"UTD.htm?2/24/2447\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef63314 \" href=\"UTD.htm?7/1/7186\">",
"     picture 2",
"    </a>",
"    ). Lesions usually involve the face and extremities. Multiple lesions may develop but tend to remain well-localized. Regional lymphadenitis may occur, although systemic symptoms are usually absent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Bullous impetigo",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bullous impetigo is a form of impetigo seen in young children in which the vesicles enlarge to form flaccid bullae with clear yellow fluid, which later becomes darker and more turbid; ruptured bullae leave a thin brown crust [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21846/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Usually there are fewer lesions than in non-bullous impetigo, and the trunk is more frequently affected.",
"   </p>",
"   <p>",
"    Bullous impetigo is due to strains of S. aureus that produce exfoliative toxin A, a toxin that causes loss of cell adhesion in the superficial epidermis by targeting the protein desmoglein 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21846/abstract/5\">",
"     5",
"    </a>",
"    ]. This mechanism is related to the pathophysiology of pemphigus, in which autoantibodies are directed against the same protein [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21846/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19146?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of pemphigus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ecthyma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ecthyma is an ulcerative form of impetigo in which the lesions extend through the epidermis and deep into the dermis. They consist of \"punched-out\" ulcers covered with yellow crust surrounded by raised violaceous margins [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21846/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     POST INFECTIOUS SEQUELAE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Poststreptococcal glomerulonephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of poststreptococcal glomerulonephritis are believed to result from streptococcal impetigo rather than streptococcal throat infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21846/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is unclear whether antimicrobial therapy for impetigo reduces the risk of poststreptococcal glomerulonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21846/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35304?source=see_link\">",
"     \"Poststreptococcal glomerulonephritis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Rheumatic fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Australian aboriginal communities, where acute rheumatic fever is hyperendemic, low rates of streptococcal pharyngitis and high rates of impetigo have been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21846/abstract/10\">",
"     10",
"    </a>",
"    ]. Observers have hypothesized that streptococcal skin infections such as impetigo may be protective against pharyngitis but may be followed by invasive sequelae such as acute rheumatic fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal pathogen is S. aureus. Beta-hemolytic streptococci (primarily group A, but occasionally other serogroups such as C and G) accounts for a minority of cases, either alone or in combination with S. aureus [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21846/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. The relative frequency of S. aureus infections has changed with time. It was predominant in the 1940s and 1950s, after which group A streptococci became more prevalent. Since the 1990s, S. aureus has become more common again [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21846/abstract/14\">",
"     14",
"    </a>",
"    ], though impetigo due to community-acquired methicillin-resistant S. aureus (CA-MRSA) has occurred in a small minority of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21846/abstract/15\">",
"     15",
"    </a>",
"    ]. This may be due, in part, to the observation that CA-MRSA strains that harbor exfoliative genes have rarely been reported; strains associated with impetigo usually have the exfoliative genes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21846/abstract/16\">",
"     16",
"    </a>",
"    ]. Bullous impetigo is caused by strains of S. aureus that produce a toxin causing cleavage in the superficial skin layer (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Bullous impetigo'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Streptococcal colonization of intact skin precedes inoculation via breaches in the skin; bacteria may be subsequently transferred from the skin to the upper respiratory tract. The group A streptococcus virulence factor, emm protein, can be encoded by one of five chromosome patterns of emm genes (denoted A through E) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21846/abstract/17\">",
"     17",
"    </a>",
"    ]. Pharyngeal strains usually have patterns A-C, while nearly all impetigo strains have patterns D or E [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21846/abstract/18\">",
"     18",
"    </a>",
"    ]. The impetigo strains patterns are rarely observed among invasive clinical isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21846/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of impetigo is made on the basis of clinical manifestations. Impetigo may be distinguished from contact dermatitis in that impetigo lesions are painful whereas contact dermatitis lesions are pruritic. Diagnostic confusion can also occur with other skin diseases including bullous pemphigoid and Stevens Johnsons syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link&amp;anchor=H53290498#H53290498\">",
"     \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Bullous pemphigoid'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cultures of pus or bullae fluid may be useful in patients who fail to respond to empiric therapy, although swabs of intact skin are not helpful and should not be performed.",
"   </p>",
"   <p>",
"    Serologic testing for streptococcal antibodies is not useful for the diagnosis of impetigo; the anti-streptolysin O (ASO) response is weak, likely because skin lipids suppress streptolysin O response [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21846/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. Anti-deoxyribonulease B (anti-Dnase B) and antihyaluronidase (AHT) response are more reliable than the ASO response following GAS skin infections. However, serologic testing can be helpful in the setting of impetigo with subsequent presumed poststreptococcal glomerulonephritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of impetigo is important for reducing spread of infection and for hastening the resolution of discomfort and cosmetic appearance [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21846/abstract/23\">",
"     23",
"    </a>",
"    ]. The treatment of impetigo should include antimicrobial therapy with activity against beta-hemolytic streptococci and S. aureus. Options include both topical and oral systemic therapy; local resistance patterns should be considered in antibiotic selection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21846/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Topical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical therapy should be administered if there are a limited number of lesions without bullae. Topical therapy has fewer side effects and lower risk for contributing to bacterial resistance compared to oral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21846/abstract/23\">",
"     23",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     Mupirocin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21651?source=see_link\">",
"     fusidic acid",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/47/4851?source=see_link\">",
"     retapamulin",
"    </a>",
"    are probably equally effective topical therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21846/abstract/23,25-33\">",
"     23,25-33",
"    </a>",
"    ]; fusidic acid is not available in the United States.",
"   </p>",
"   <p>",
"    An alternative to topical antibiotics is",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    cream; it was as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21651?source=see_link\">",
"     fusidic acid",
"    </a>",
"    in a randomized trial of 256 patients with impetigo (efficacy 70 to 80 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21846/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the components of over-the-counter triple antibiotic ointments (consisting of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/14/18660?source=see_link\">",
"     bacitracin-neomycin-polymyxin B",
"    </a>",
"    ) do have some activity against the organisms causing impetigo, they may not be as effective for treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21846/abstract/27\">",
"     27",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6469?source=see_link\">",
"     Bacitracin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"     neomycin",
"    </a>",
"    can also cause contact dermatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Oral antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral antibiotic therapy should be used for impetigo when the lesions are bullous, and when it is impractical to use topical therapy either due to the extent or location of lesions. Appropriate agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/11/3253?source=see_link\">",
"     dicloxacillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"     cephalexin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef78882 \" href=\"UTD.htm?23/12/23755\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21846/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. In the setting of beta-lactam allergy or suspected MRSA (",
"    <a class=\"graphic graphic_table graphicRef53504 \" href=\"UTD.htm?5/9/5275\">",
"     table 2",
"    </a>",
"    ), appropriate choices are outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef64178 \" href=\"UTD.htm?9/57/10140\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=see_link\">",
"     \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33290?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children\", section on 'Antimicrobial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Macrolides are not adequate therapy given increasing resistance among S. pyogenes and S. aureus [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21846/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Penicillin was previously useful for treatment of impetigo but is no longer adequate given the significant role of S. aureus (most strains of which produce beta-lactamase that can inactivate penicillin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21846/abstract/32\">",
"     32",
"    </a>",
"    ]. Fluoroquinolones should NOT be used to treat impetigo, as MRSA resistance to this class is widespread and resistance can develop on therapy.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     Trimethoprim-sulfamethoxazole",
"    </a>",
"    has activity against MRSA but does not have activity against streptococci. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=see_link\">",
"     \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33290?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children\", section on 'Antimicrobial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of antimicrobial therapy should be tailored to clinical improvement; seven days of treatment is usually sufficient [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21846/abstract/33\">",
"     33",
"    </a>",
"    ]. Crusted lesions can be washed gently. Handwashing is important for reducing spread among children, and other preventive measures employed in reducing the spread of staphylococci may also be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21846/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17338?source=see_link\">",
"     \"Prevention and control of methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/18/26913?source=see_link\">",
"       \"Patient information: Impetigo (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/55/8048?source=see_link\">",
"       \"Patient information: Impetigo (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impetigo is a contagious superficial bacterial infection manifesting on the face and extremities with lesions that progress from papules to vesicles, pustules, and crusts. Less common manifestations include bullous impetigo and ecthyma. Impetigo may be followed by poststreptococcal glomerulonephritis or rheumatic fever. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The principal pathogen is S. aureus; beta-hemolytic streptococci (primarily group A, but occasionally other serogroups such as C and G) cause a minority of cases, either alone or in combination with S. aureus. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For management of impetigo with a small number of non-bullous lesions, we recommend treatment with topical therapy rather than oral therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all other forms of impetigo, we recommend treatment with oral antibiotic therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Appropriate agents include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/11/3253?source=see_link\">",
"       dicloxacillin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"       cephalexin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      &nbsp;(",
"      <a class=\"graphic graphic_table graphicRef78882 \" href=\"UTD.htm?23/12/23755\">",
"       table 1",
"      </a>",
"      ). In the setting of beta-lactam allergy or suspected MRSA, appropriate choices include clindamycin or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      &nbsp;(",
"      <a class=\"graphic graphic_table graphicRef57196 \" href=\"UTD.htm?39/12/40139\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The duration of antimicrobial therapy should be tailored to clinical improvement; seven days is usually sufficient. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Handwashing is important for reducing spread among children, and other preventive measures employed in reducing the spread of staphylococci may also be helpful. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17338?source=see_link\">",
"       \"Prevention and control of methicillin-resistant Staphylococcus aureus in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/1\">",
"      Lejbkowicz F, Samet L, Belavsky L, Bitterman-Deutsch O. Impetigo in soldiers after hand-to-hand combat training. Mil Med 2005; 170:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/2\">",
"      Dajani AS, Ferrieri P, Wannamaker LW. Natural history of impetigo. II. Etiologic agents and bacterial interactions. J Clin Invest 1972; 51:2863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/3\">",
"      Edlich RF, Winters KL, Britt LD, Long WB 3rd. Bacterial diseases of the skin. J Long Term Eff Med Implants 2005; 15:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/4\">",
"      Hirschmann JV. Impetigo: etiology and therapy. Curr Clin Top Infect Dis 2002; 22:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/5\">",
"      Amagai M, Matsuyoshi N, Wang ZH, et al. Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1. Nat Med 2000; 6:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/6\">",
"      Stanley JR, Amagai M. Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. N Engl J Med 2006; 355:1800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/7\">",
"      Hewitt WD, Farrar WE. Bacteremia and ecthyma caused by Streptococcus pyogenes in a patient with acquired immunodeficiency syndrome. Am J Med Sci 1988; 295:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/8\">",
"      Baltimore RS. Treatment of impetigo: a review. Pediatr Infect Dis 1985; 4:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/9\">",
"      Weinstein L, Le Frock J. Does antimicrobial therapy of streptococcal pharyngitis or pyoderma alter the risk of glomerulonephritis? J Infect Dis 1971; 124:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/10\">",
"      McDonald MI, Towers RJ, Andrews RM, et al. Low rates of streptococcal pharyngitis and high rates of pyoderma in Australian aboriginal communities where acute rheumatic fever is hyperendemic. Clin Infect Dis 2006; 43:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/11\">",
"      Darmstadt GL, Lane AT. Impetigo: an overview. Pediatr Dermatol 1994; 11:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/12\">",
"      Demidovich CW, Wittler RR, Ruff ME, et al. Impetigo. Current etiology and comparison of penicillin, erythromycin, and cephalexin therapies. Am J Dis Child 1990; 144:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/13\">",
"      Baddour LM. Primary skin infections in primary care: An update. Infect Med 1993; 10:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/14\">",
"      Dagan R. Impetigo in childhood: changing epidemiology and new treatments. Pediatr Ann 1993; 22:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/15\">",
"      Liu Y, Kong F, Zhang X, et al. Antimicrobial susceptibility of Staphylococcus aureus isolated from children with impetigo in China from 2003 to 2007 shows community-associated methicillin-resistant Staphylococcus aureus to be uncommon and heterogeneous. Br J Dermatol 2009; 161:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/16\">",
"      Del Giudice P, Hubiche P. Community-associated methicillin-resistant Staphylococcus aureus and impetigo. Br J Dermatol 2010; 162:905; author reply 905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/17\">",
"      Wasserzug O, Valinsky L, Klement E, et al. A cluster of ecthyma outbreaks caused by a single clone of invasive and highly infective Streptococcus pyogenes. Clin Infect Dis 2009; 48:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/18\">",
"      Bessen DE, Sotir CM, Readdy TL, Hollingshead SK. Genetic correlates of throat and skin isolates of group A streptococci. J Infect Dis 1996; 173:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/19\">",
"      Fiorentino TR, Beall B, Mshar P, Bessen DE. A genetic-based evaluation of the principal tissue reservoir for group A streptococci isolated from normally sterile sites. J Infect Dis 1997; 176:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/20\">",
"      Kaplan EL, Anthony BF, Chapman SS, et al. The influence of the site of infection on the immune response to group A streptococci. J Clin Invest 1970; 49:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/21\">",
"      Bisno AL, Nelson KE, Waytz P, Brunt J. Factors influencing serum antibody responses in streptococcal pyoderma. J Lab Clin Med 1973; 81:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/22\">",
"      Kaplan EL, Wannamaker LW. Suppression of the antistreptolysin O response by cholesterol and by lipid extracts of rabbit skin. J Exp Med 1976; 144:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/23\">",
"      Koning S, van der Sande R, Verhagen AP, et al. Interventions for impetigo. Cochrane Database Syst Rev 2012; 1:CD003261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/24\">",
"      Yun HJ, Lee SW, Yoon GM, et al. Prevalence and mechanisms of low- and high-level mupirocin resistance in staphylococci isolated from a Korean hospital. J Antimicrob Chemother 2003; 51:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/25\">",
"      Koning S, Verhagen AP, van Suijlekom-Smit LW, et al. Interventions for impetigo. Cochrane Database Syst Rev 2004; :CD003261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/26\">",
"      Christensen OB, Anehus S. Hydrogen peroxide cream: an alternative to topical antibiotics in the treatment of impetigo contagiosa. Acta Derm Venereol 1994; 74:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/27\">",
"      Bass JW, Chan DS, Creamer KM, et al. Comparison of oral cephalexin, topical mupirocin and topical bacitracin for treatment of impetigo. Pediatr Infect Dis J 1997; 16:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/28\">",
"      Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/29\">",
"      Kumar A, Murray DL, Hanna CB, et al. Comparative study of cephalexin hydrochloride and cephalexin monohydrate in the treatment of skin and soft tissue infections. Antimicrob Agents Chemother 1988; 32:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/30\">",
"      Daniel R. Azithromycin, erythromycin and cloxacillin in the treatment of infections of skin and associated soft tissues. European Azithromycin Study Group. J Int Med Res 1991; 19:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/31\">",
"      Parish LC. Clarithromycin in the treatment of skin and skin structure infections: two multicenter clinical studies. Clarithromycin Study Group. Int J Dermatol 1993; 32:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/32\">",
"      Ferrieri P, Dajani AS, Wannamaker LW. A controlled study of penicillin prophylaxis against streptococcal impetigo. J Infect Dis 1974; 129:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/33\">",
"      George A, Rubin G. A systematic review and meta-analysis of treatments for impetigo. Br J Gen Pract 2003; 53:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/34\">",
"      Luby SP, Agboatwalla M, Feikin DR, et al. Effect of handwashing on child health: a randomised controlled trial. Lancet 2005; 366:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21846/abstract/35\">",
"      Kowalski TJ, Berbari EF, Osmon DR. Epidemiology, treatment, and prevention of community-acquired methicillin-resistant Staphylococcus aureus infections. Mayo Clin Proc 2005; 80:1201.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7655 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-201.211.0.116-B662D4775B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_21_21846=[""].join("\n");
var outline_f21_21_21846=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Non-bullous impetigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Bullous impetigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ecthyma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      POST INFECTIOUS SEQUELAE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Poststreptococcal glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Topical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Oral antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/7655\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/7655|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/24/2447\" title=\"picture 1\">",
"      Impetigo vesiculopustules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/1/7186\" title=\"picture 2\">",
"      Impetigo of the face",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/7655|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/12/23755\" title=\"table 1\">",
"      Antimicrobial therapy impetigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/9/5275\" title=\"table 2\">",
"      Risk factors for MRSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/57/10140\" title=\"table 3\">",
"      Oral antibiotics for infections due to MRSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/12/40139\" title=\"table 4\">",
"      Parenteral antibiotics for infections due to MRSA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=related_link\">",
"      Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33290?source=related_link\">",
"      Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19146?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of pemphigus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/55/8048?source=related_link\">",
"      Patient information: Impetigo (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/18/26913?source=related_link\">",
"      Patient information: Impetigo (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35304?source=related_link\">",
"      Poststreptococcal glomerulonephritis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17338?source=related_link\">",
"      Prevention and control of methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=related_link\">",
"      Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_21_21847="Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)";
var content_f21_21_21847=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/21/21847/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/21/21847/contributors\">",
"     Joseph A Eustace, MB, MHS, MRCPI",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/21/21847/contributors\">",
"     Sinead Kinsella, MD, MBS, MRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/21/21847/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/21/21847/contributors\">",
"     Paul M Palevsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/21/21847/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/21/21847/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/21/21847/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H25398971\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute kidney injury (AKI) can occur in patients who have rhabdomyolysis and, less commonly, in patients with hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21847/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In both groups of patients, AKI is caused by the non-protein heme pigment that is released from either myoglobin or hemoglobin and is toxic to the kidney.",
"   </p>",
"   <p>",
"    The prevention and treatment of heme pigment-induced AKI due to nontraumatic rhabdomyolysis or hemolysis will be reviewed here. The clinical features and diagnosis of this disorder, AKI due to traumatic muscle injury, overviews of rhabdomyolysis and hemolysis, and the general management of oliguric acute renal failure and its complications, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=see_link\">",
"     \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15369?source=see_link\">",
"     \"Crush-related acute kidney injury (acute renal failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=see_link\">",
"     \"Approach to the diagnosis of hemolytic anemia in the adult\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4696?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25398978\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to treating the underlying rhabdomyolysis or hemolysis, the general goals for preventive therapy in all patients at risk for heme pigment-induced AKI are twofold:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Correction of volume depletion, if present",
"     </li>",
"     <li>",
"      Prevention of intratubular cast formation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These issues are reviewed here. The prevention of AKI in patients who have suffered trauma and are entrapped at the site of trauma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15369?source=see_link&amp;anchor=H10#H10\">",
"     \"Crush-related acute kidney injury (acute renal failure)\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The general approaches to the treatment of the factor(s) causing rhabdomyolysis (including an acute compartment syndrome) or hemolysis are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link\">",
"     \"Acute compartment syndrome of the extremities\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/46/43753?source=see_link\">",
"     \"Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25398985\">",
"    <span class=\"h2\">",
"     Volume administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to treating the underlying rhabdomyolysis or hemolysis, the prevention of AKI requires early and aggressive fluid resuscitation. The goals of volume repletion are to maintain or enhance renal perfusion, thereby minimizing ischemic injury, and to increase the urine flow rate which will limit intratubular cast formation, wash out partially obstructing intratubular casts, and increase urinary potassium excretion.",
"   </p>",
"   <p>",
"    Intravenous isotonic saline should be administered as soon as possible after the onset of injury or detection of hemolysis, and continued until the muscle injury or hemolysis has resolved. The evidence to support this strategy is largely based upon studies of traumatic crush injuries that have resulted from large scale natural or man-made disasters. Although these studies are predominantly retrospective and underpowered, they are believed to be broadly applicable to AKI that is due to non-traumatic rhabdomyolysis and to hemolysis as well, given their common underlying pathogeneses. These studies are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15369?source=see_link\">",
"     \"Crush-related acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal fluid and rate of repletion are unclear. No studies have directly compared the efficacy and safety of different types and rates of fluid administration in this setting. In addition, the total amount and rate of volume repletion will vary depending on the underlying cause of rhabdomyolysis and hemolysis.",
"   </p>",
"   <p>",
"    As an example, attempted aggressive volume resuscitation in the setting of massive hemolysis may result in volume overload and pulmonary edema. In contrast, volume overload is less likely to occur in patients with rhabdomyolysis, at least during its initial stages, due to the sequestration of fluid within damaged muscle.",
"   </p>",
"   <p>",
"    For patients who are at risk for heme-associated AKI due to rhabdomyolysis from any cause, we suggest initial fluid resuscitation with isotonic saline at a rate of 1 to 2",
"    <span class=\"nowrap\">",
"     L/hour.",
"    </span>",
"    The plasma creatinine kinase (CK) concentration correlates with the severity of muscle injury and concentrations &gt;5000",
"    <span class=\"nowrap\">",
"     U/L",
"    </span>",
"    identify patients who are at risk for the development of AKI. However, it may be difficult to identify patients who are at high risk for AKI based upon the initial plasma CK value since the CK level may still be rising from ongoing muscle injury. All patients should be initially treated with vigorous fluid repletion until it is clear from sequential laboratory values that the plasma CK level is stable and not increasing. Patients who have a stable plasma CK level less than 5000",
"    <span class=\"nowrap\">",
"     U/L",
"    </span>",
"    do not require intravenous fluid since studies have shown that the risk of AKI is low among such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21847/abstract/3-6\">",
"     3-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fluid requirements may be less among patients with hemolysis who are generally less volume depleted than patients who have rhabdomyolysis. In patients who are at risk for heme-associated AKI due to hemolysis, we suggest isotonic saline at an initial rate of 100 to 200",
"    <span class=\"nowrap\">",
"     mL/hour.",
"    </span>",
"    The degree of hemolysis that is associated with the risk of AKI is not known. All patients should be initially treated with intravenous saline, providing volume overload is not present.",
"   </p>",
"   <p>",
"    The volume status of the patient should be carefully assessed and urine output monitored. The initial rate is continued until the systemic blood pressure normalizes and urine output is established, or there is evidence of volume overload. Volume overload is defined by signs of pulmonary congestion or via central hemodynamic monitoring, since peripheral edema may be present even in the absence of volume overload due to third space sequestration. If a diuresis is established, fluids are titrated to maintain a urine output of 200 to 300",
"    <span class=\"nowrap\">",
"     mL/hour.",
"    </span>",
"   </p>",
"   <p>",
"    Among patients with rhabdomyolysis, fluid repletion should be continued until plasma CK levels decrease to less than 5000",
"    <span class=\"nowrap\">",
"     U/L",
"    </span>",
"    and urine is dipstick negative for hematuria. Studies have shown that there is a low likelihood of acute renal failure when peak creatine kinase levels are under 5000 to 10,000",
"    <span class=\"nowrap\">",
"     U/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21847/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Among patients with hemolysis, LDH and hemoglobin levels should be monitored to guide intravenous fluid therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=see_link&amp;anchor=H11512190#H11512190\">",
"     \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\", section on 'Other laboratory findings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25398992\">",
"    <span class=\"h2\">",
"     Bicarbonate",
"    </span>",
"    &nbsp;&mdash;&nbsp;A forced alkaline diuresis, in which the urine pH is raised to above 6.5, may diminish the renal toxicity of heme. In theory, urine alkalinization prevents heme-protein precipitation with Tamm-Horsfall protein, and therefore intratubular pigment cast formation. Alkalinization may also decrease the release of free iron from myoglobin and the formation of F2-isoprostanes, which may enhance renal vasoconstriction and decrease the risk for tubular precipitation of uric acid [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21847/abstract/1,2,7\">",
"     1,2,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these potential benefits, there is no clear clinical evidence that an alkaline diuresis is more effective than a saline diuresis in preventing AKI [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21847/abstract/8\">",
"     8",
"    </a>",
"    ]. The only data in support of an alkaline diuresis are derived from uncontrolled case series in which a benefit was demonstrated among patients with severe rhabdomyolysis. These data are discussed elsewhere. Data on the combination of bicarbonate and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    are presented below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15369?source=see_link&amp;anchor=H14#H14\">",
"     \"Crush-related acute kidney injury (acute renal failure)\", section on 'Use of bicarbonate'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H25398999\">",
"     'Loop diuretics and mannitol'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition to a lack of clear evidence of benefit, maintaining the urine pH above 6.5 is difficult in patients with AKI. There are also potential risks to alkalinization of the plasma, such as promoting calcium phosphate deposition (which is more likely if hyperphosphatemia is present), and inducing or worsening the manifestations of hypocalcemia by both a direct membrane effect and a reduction in ionized calcium levels [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21847/abstract/1\">",
"     1",
"    </a>",
"    ]. Manifestations of severe hypocalcemia include tetany, seizures, and cardiac arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36646?source=see_link\">",
"     \"Clinical manifestations of hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite these limitations, patients who are appropriately monitored may benefit from bicarbonate therapy. We generally administer a bicarbonate infusion to patients who have severe rhabdomyolysis, such as those with a serum CK above 5000",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    or clinical evidence of severe muscle injury (eg, crush injury) and a rising serum CK, regardless of the initial value. In such patients, bicarbonate may be given, providing the following conditions are met:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe hypocalcemia is not present",
"     </li>",
"     <li>",
"      Arterial pH is less than 7.50",
"     </li>",
"     <li>",
"      Serum bicarbonate is less 30",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We infuse 130",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    (150 mL [3 amps] of 8.4 percent sodium bicarbonate mixed with 1 L of 5 percent dextrose or water)",
"    <strong>",
"    </strong>",
"    via an intravenous line separate from that used for the isotonic saline infusion. The initial rate of infusion is 200",
"    <span class=\"nowrap\">",
"     mL/hour;",
"    </span>",
"    the rate is adjusted to achieve a urine pH of &gt;6.5.",
"   </p>",
"   <p>",
"    If bicarbonate is given, the arterial pH and serum calcium should be monitored every two hours during the infusion. The bicarbonate infusion should be discontinued if the urine pH does not rise above 6.5 after three to four hours, if the patient develops symptomatic hypocalcemia, if the arterial pH exceeds 7.5 or if the serum bicarbonate exceeds 30",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    If the bicarbonate solution is discontinued, volume repletion should be continued with isotonic saline.",
"   </p>",
"   <p>",
"    The use of bicarbonate has not been evaluated in patients with hemolysis. We generally do",
"    <strong>",
"     not",
"    </strong>",
"    administer bicarbonate to such patients unless another indication is present (such as concurrent rhabdomyolysis which may occur in the settings of envenomation and poisonings). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=see_link&amp;anchor=H11512162#H11512162\">",
"     \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\", section on 'Causes of hemolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a diuresis is established, we suggest continuing bicarbonate therapy until plasma CK decreases to less than 5000",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    or symptomatic fluid overload develops.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25398999\">",
"    <span class=\"h2\">",
"     Loop diuretics and mannitol",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of loop diuretics or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    in rhabdomyolysis is not established. Experimental studies suggested that mannitol might be protective by causing a diuresis, which minimizes intratubular heme pigment deposition and cast formation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by acting as a free radical scavenger, thereby minimizing cell injury [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21847/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. However, mannitol did not ameliorate proximal tubular necrosis, suggesting the induced diuresis was of primary importance [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21847/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The available retrospective series in humans reported conflicting results regarding the effectiveness of combined administration of bicarbonate and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    in preventing heme pigment induced ATN [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21847/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. In a series of 382 patients with serum CK concentration &gt;5000",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    154 (40 percent) were treated with bicarbonate and mannitol [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21847/abstract/14\">",
"     14",
"    </a>",
"    ]. There was no statistically significant difference in the incidence of renal failure (defined as serum creatinine &gt;2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [177",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    (22 versus 18 percent), dialysis (7 versus 6 percent), or death (15 versus 18 percent) in patients who were or were not treated with bicarbonate and mannitol, respectively. However, there was a trend toward improved outcomes in patients with extremely high serum CK levels (greater than 30,000",
"    <span class=\"nowrap\">",
"     U/L)",
"    </span>",
"    treated with bicarbonate and mannitol.",
"   </p>",
"   <p>",
"    Unless the patient is carefully monitored and losses replaced when appropriate,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    can lead to both volume depletion and, since free water is lost with mannitol, hypernatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21847/abstract/9\">",
"     9",
"    </a>",
"    ]. Mannitol administered in very high doses, or to patients with reduced renal excretion due to renal insufficiency, can cause hyperosmolality, volume expansion and hyperosmolar hyponatremia. The increase in plasma osmolality can also cause passive movement of potassium out of cells and raise the plasma potassium concentration. Acute renal failure may occur if patients are treated with more than 200 g of mannitol per day. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32451?source=see_link\">",
"     \"Complications of mannitol therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The net clinical benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    remains uncertain and, therefore, we do not routinely administer it. The use of mannitol administration may be of benefit in patients with marked elevations in CK (&gt;30,000",
"    <span class=\"nowrap\">",
"     U/L),",
"    </span>",
"    however, even in these patients with severe rhabdomyolysis, the true benefit associated with mannitol administration remains undefined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15369?source=see_link&amp;anchor=H15#H15\">",
"     \"Crush-related acute kidney injury (acute renal failure)\", section on 'Use of mannitol'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    is given, providing the urinary flow is adequate (defined as &gt;20",
"    <span class=\"nowrap\">",
"     mL/hour),",
"    </span>",
"    adding 50 mL of 20 percent mannitol (1 to 2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day [total, 120 g], given at a rate of 5 g per hour) to each liter of fluid is suggested. Mannitol is contraindicated in patients with oligoanuria.",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    is given, the plasma osmolal gap should be measured, and mannitol discontinued if the osmolal gap rises above 55",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?27/45/28370?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?20/19/20786?source=see_link\">",
"     calculator 2",
"    </a>",
"    ). Mannitol should be discontinued if the desired diuresis of approximately 200 to 300",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    cannot be achieved, since there is a risk of hyperosmolality, volume overload, and hyperkalemia with continued mannitol administration under these conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32451?source=see_link\">",
"     \"Complications of mannitol therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Loop diuretics have no impact on outcome in AKI [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21847/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In the context of rhabdomyolysis, loop diuretics may worsen the already existing trend for hypocalcemia, since they induce calciuria and may increase the risk of cast formation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21847/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42154?source=see_link\">",
"     \"Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite these concerns, however, judicious use of loop diuretics may be justified in patients with rhabdomyolysis or hemolysis if there is evidence of volume overload.",
"   </p>",
"   <p>",
"    Patients who remain oliguric or anuric despite aggressive volume resuscitation should be considered to have established AKI. Among such patients, the rate of fluid administration should be decreased to a rate sufficient to maintain circulatory support. Such patients should be closely followed for indications to initiate dialysis. (See",
"    <a class=\"local\" href=\"#H25399021\">",
"     'Treatment of established AKI'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15140029\">",
"    <span class=\"h2\">",
"     Dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of dialysis to remove myoglobin, hemoglobin or uric acid in order to prevent the development of renal injury has not been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21847/abstract/3,19\">",
"     3,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25399006\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25399014\">",
"    <span class=\"h2\">",
"     Treatment of metabolic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be closely followed for the development of metabolic abnormalities including hyperkalemia, hypocalcemia, hyperphosphatemia, and hyperuricemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=see_link&amp;anchor=H11512176#H11512176\">",
"     \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To minimize the late occurrence of hypercalcemia, calcium supplementation for hypocalcemia should be avoided unless significant signs and symptoms of hypocalcemia develop or calcium administration is required for the management of hyperkalemia.",
"   </p>",
"   <p>",
"    Hyperkalemia should be anticipated and may occur even in the absence of severe renal failure. Hyperkalemia should be aggressively treated. Dialysis may be required to treat severe hyperkalemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link\">",
"     \"Treatment and prevention of hyperkalemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who develop hyperuricemia should be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    . Allopurinol should be given orally at 300 mg if uric acid levels are &gt;8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (476",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    or if there is a 25 percent increase from baseline. Allopurinol is not indicated in the treatment of hemolysis in the absence of hyperuricemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25399021\">",
"    <span class=\"h2\">",
"     Treatment of established AKI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other than maintenance of fluid and electrolyte balance and tissue perfusion, there is no specific therapy once the patient has developed AKI. The initiation of dialysis may be necessary for control of volume overload, hyperkalemia, severe acidemia, and uremia. A detailed discussion of the indications for dialysis is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Peritoneal dialysis may not be sufficient to achieve adequate metabolic control in patients with severe rhabdomyolysis, which may necessitate frequent hemodialysis or the use of high dose continuous renal replacement therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21847/abstract/2,19\">",
"     2,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25399028\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall prognosis for patients with heme-induced AKI is favorable, as most survivors recover sufficient kidney function to be dialysis-independent and many will recover to normal or near normal kidney function [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21847/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/59/22450?source=see_link\">",
"       \"Patient information: Rhabdomyolysis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25399035\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with rhabdomyolysis are at risk for heme-induced AKI. Early and aggressive fluid resuscitation is the major preventive therapy. We recommend that all patients with rhabdomyolysis who have plasma CK values &gt;5000",
"      <span class=\"nowrap\">",
"       U/L",
"      </span>",
"      and those who have CK values that are increasing regardless of baseline value, be administered intravenous fluid (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25398985\">",
"       'Volume administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal fluid for the prevention of heme-induced AKI is not known. For patients with rhabdomyolysis who are to receive intravenous fluid, we suggest initial volume repletion with isotonic saline rather than other fluids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25398985\">",
"       'Volume administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal rate of repletion for the prevention of heme-induced AKI is not known. For patients with rhabdomyolysis who are to receive intravenous fluid we suggest initial volume repletion at a rate of 1 to 2",
"      <span class=\"nowrap\">",
"       L/hour",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The rate is adjusted to maintain the desired diuresis of approximately 200 to 300",
"      <span class=\"nowrap\">",
"       mL/hour.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H25398985\">",
"       'Volume administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Heme-induced AKI from hemolysis may also be prevented by volume repletion. The volume requirements for patients with hemolysis are generally less than the volume requirements of patients with rhabdomyolysis. For patients at risk for heme-induced AKI from hemolysis, we suggest initial volume repletion with isotonic saline at a rate of 100 to 200",
"      <span class=\"nowrap\">",
"       mL/hour",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25398985\">",
"       'Volume administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Limited data suggest that alkalinization of urine may benefit patients with severe rhabdomyolysis. The administration of bicarbonate may cause severe alkalosis among anuric patients. For patients with rhabdomyolysis in whom a diuresis is established with volume repletion, we suggest the administration of an alkaline solution, providing the patient is not severely hypocalcemic, and has an arterial pH less than 7.5 and a serum bicarbonate less than 30",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25398992\">",
"       'Bicarbonate'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15369?source=see_link&amp;anchor=H14#H14\">",
"       \"Crush-related acute kidney injury (acute renal failure)\", section on 'Use of bicarbonate'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The alkaline solution should be discontinued if the urine pH does not rise above 6.5 after three to four hours of the alkaline solution, if the arterial pH increases to 7.5, if the serum bicarbonate exceeds 30",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      or if symptomatic hypocalcemia develops. If the bicarbonate solution is discontinued, volume repletion should be continued with isotonic saline. (See",
"      <a class=\"local\" href=\"#H25398992\">",
"       'Bicarbonate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Loop diuretics have not been shown to be effective in preventing heme-pigment induced AKI but may be given to patients who develop volume overload as a result of aggressive volume administration. (See",
"      <a class=\"local\" href=\"#H25398999\">",
"       'Loop diuretics and mannitol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plasma potassium and calcium should be monitored several times daily until stable. Hyperkalemia should be treated as discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link\">",
"       \"Treatment and prevention of hyperkalemia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Calcium supplementation should be given only for symptomatic hypocalcemia or severe hyperkalemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=see_link\">",
"       \"Treatment of hypocalcemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link\">",
"       \"Treatment and prevention of hyperkalemia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dialysis may be necessary for control of hyperkalemia and correction of acidosis, or for the treatment of volume overload. (See",
"      <a class=\"local\" href=\"#H25399021\">",
"       'Treatment of established AKI'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21847/abstract/1\">",
"      Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore) 2005; 84:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21847/abstract/2\">",
"      Vanholder R, Sever MS, Erek E, Lameire N. Rhabdomyolysis. J Am Soc Nephrol 2000; 11:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21847/abstract/3\">",
"      Mikkelsen TS, Toft P. Prognostic value, kinetics and effect of CVVHDF on serum of the myoglobin and creatine kinase in critically ill patients with rhabdomyolysis. Acta Anaesthesiol Scand 2005; 49:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21847/abstract/4\">",
"      de Meijer AR, Fikkers BG, de Keijzer MH, et al. Serum creatine kinase as predictor of clinical course in rhabdomyolysis: a 5-year intensive care survey. Intensive Care Med 2003; 29:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21847/abstract/5\">",
"      Hatamizadeh P, Najafi I, Vanholder R, et al. Epidemiologic aspects of the Bam earthquake in Iran: the nephrologic perspective. Am J Kidney Dis 2006; 47:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21847/abstract/6\">",
"      Veenstra J, Smit WM, Krediet RT, Arisz L. Relationship between elevated creatine phosphokinase and the clinical spectrum of rhabdomyolysis. Nephrol Dial Transplant 1994; 9:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21847/abstract/7\">",
"      Malik GH. Rhabdomyolysis and Myoglobin-induced Acute Renal Failure. Saudi J Kidney Dis Transpl 1998; 9:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21847/abstract/8\">",
"      Huerta-Alard&iacute;n AL, Varon J, Marik PE. Bench-to-bedside review: Rhabdomyolysis -- an overview for clinicians. Crit Care 2005; 9:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21847/abstract/9\">",
"      Zager RA. Combined mannitol and deferoxamine therapy for myohemoglobinuric renal injury and oxidant tubular stress. Mechanistic and therapeutic implications. J Clin Invest 1992; 90:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21847/abstract/10\">",
"      Odeh M. The role of reperfusion-induced injury in the pathogenesis of the crush syndrome. N Engl J Med 1991; 324:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21847/abstract/11\">",
"      Ron D, Taitelman U, Michaelson M, et al. Prevention of acute renal failure in traumatic rhabdomyolysis. Arch Intern Med 1984; 144:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21847/abstract/12\">",
"      Gunal AI, Celiker H, Dogukan A, et al. Early and vigorous fluid resuscitation prevents acute renal failure in the crush victims of catastrophic earthquakes. J Am Soc Nephrol 2004; 15:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21847/abstract/13\">",
"      Homsi E, Barreiro MF, Orlando JM, Higa EM. Prophylaxis of acute renal failure in patients with rhabdomyolysis. Ren Fail 1997; 19:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21847/abstract/14\">",
"      Brown CV, Rhee P, Chan L, et al. Preventing renal failure in patients with rhabdomyolysis: do bicarbonate and mannitol make a difference? J Trauma 2004; 56:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21847/abstract/15\">",
"      Lameire N, Vanholder R, Van Biesen W. Loop diuretics for patients with acute renal failure: helpful or harmful? JAMA 2002; 288:2599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21847/abstract/16\">",
"      Mehta RL, Pascual MT, Soroko S, et al. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA 2002; 288:2547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21847/abstract/17\">",
"      Slater MS, Mullins RJ. Rhabdomyolysis and myoglobinuric renal failure in trauma and surgical patients: a review. J Am Coll Surg 1998; 186:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21847/abstract/18\">",
"      Sever MS, Vanholder R, Lameire N. Management of crush-related injuries after disasters. N Engl J Med 2006; 354:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21847/abstract/19\">",
"      Holt S, Moore K. Pathogenesis of renal failure in rhabdomyolysis: the role of myoglobin. Exp Nephrol 2000; 8:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21847/abstract/20\">",
"      Woodrow G, Brownjohn AM, Turney JH. The clinical and biochemical features of acute renal failure due to rhabdomyolysis. Ren Fail 1995; 17:467.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14036 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-5AC2A9890B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_21_21847=[""].join("\n");
var outline_f21_21_21847=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25399035\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25398971\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25398978\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25398985\">",
"      Volume administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25398992\">",
"      Bicarbonate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25398999\">",
"      Loop diuretics and mannitol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15140029\">",
"      Dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25399006\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25399014\">",
"      Treatment of metabolic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25399021\">",
"      Treatment of established AKI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25399028\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25399035\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?27/45/28370?source=related_link\" title=\"calculator 1\">",
"      Calculator: Serum osmolal gap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?20/19/20786?source=related_link\" title=\"calculator 2\">",
"      Calculator: Serum osmolal gap (SI units)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=related_link\">",
"      Acute compartment syndrome of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=related_link\">",
"      Approach to the diagnosis of hemolytic anemia in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=related_link\">",
"      Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36646?source=related_link\">",
"      Clinical manifestations of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32451?source=related_link\">",
"      Complications of mannitol therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15369?source=related_link\">",
"      Crush-related acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/46/43753?source=related_link\">",
"      Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/59/22450?source=related_link\">",
"      Patient information: Rhabdomyolysis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42154?source=related_link\">",
"      Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4696?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=related_link\">",
"      Treatment and prevention of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=related_link\">",
"      Treatment of hypocalcemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_21_21848="Coccidioidomycosis in compromised hosts";
var content_f21_21_21848=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"63\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Coccidioidomycosis in compromised hosts",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/21/21848/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/21/21848/contributors\">",
"     John N Galgiani, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/21/21848/contributors\">",
"     Neil M Ampel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/21/21848/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/21/21848/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/21/21848/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/21/21848/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/21/21848/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coccidioidomycosis is usually a self-limited infection, resulting in lifelong immunity. Approximately 150,000 coccidioidal infections occur each year resulting in an estimated 50,000 illnesses; of these only a few experience progressive pneumonia or spread of the infection to other parts of the body. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=see_link\">",
"     \"Primary coccidioidal infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/51/39734?source=see_link\">",
"     \"Management of pulmonary sequelae and complications of coccidioidomycosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26807?source=see_link\">",
"     \"Manifestations and treatment of extrapulmonary coccidioidomycosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For some of those infected, no apparent underlying medical condition appears to account for the development of complications. However, altered host immunity by identifiable predisposing diseases or drug therapies increasingly seems to be responsible for complications. Since the etiologies of immunosuppression are numerous and their effects vary in scope and depth, the exact effect of a specific immunosuppressive condition upon the course of a coccidioidal infection is not always predictable.",
"   </p>",
"   <p>",
"    Some of the most well-known factors that have been associated with disseminated infection and emerging strategies for reducing their risk will be reviewed here. This has been an evolving field, and as more experience is obtained with coccidioidomycosis in immunocompromised patients, it is likely that recommendations will continue to change.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFECT ON DISEASE EXPRESSION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Increased disease severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppression affects the clinical severity of coccidioidomycosis primarily by increasing the risk of extrapulmonary dissemination. This observation was first suggested in case reports but later was established by measuring the incidence of dissemination within defined populations of susceptible hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In renal transplant recipients, for example, three-quarters of diagnosed infections resulted in extrapulmonary lesions, perhaps 50- to 200-fold higher than in contemporaneous normal populations. In patients with rheumatologic diseases, the increased use of immunosuppressive regimens, including anti-TNF therapies, also carries the risk of more extensive coccidioidal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The finding of a diffuse reticulonodular pneumonia, the result of hematogenous seeding of the lungs associated with fungemia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/5\">",
"     5",
"    </a>",
"    ], is also most common in immunosuppressed patients. As an example, in a series of 300 patients hospitalized for coccidioidal pneumonia, diffuse pneumonia was identified in 13, and of these 13, all but three had an underlying immunocompromising condition [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/51/39734?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of pulmonary sequelae and complications of coccidioidomycosis\", section on 'Diffuse reticulonodular pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Sites of infection and histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated coccidioidal lesions tend to occur in the same locations regardless of the immune status of the host (eg, in or under the skin, in the skeletal system, or in the meninges) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75408 \" href=\"UTD.htm?39/62/40930\">",
"     image 1",
"    </a>",
"    ). However, in addition to these sites, patients with profound immunosuppression are more likely to experience other lesions including in the inguinal lymph nodes, the liver, and subserosally in the intestines [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Granulomatous responses by histology are also less formed in the lesions of the most immunosuppressed patients and contain a greater number of organisms than in immunocompetent or less immunosuppressed hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Reactivation of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition, immunosuppression can reactivate previously acquired latent coccidioidal infection. Although normal immunologic control results in resolution of illness, it appears to do so without eradicating the Coccidioides from the body. As an example, stable asymptomatic solitary pulmonary nodules can yield viable Coccidioides [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/10\">",
"     10",
"    </a>",
"    ]. This suggests that infections might be controlled by inducing dormancy rather than by killing the organism. Since growth occurs when Coccidioides is removed from tissue, the dormant state appears to be a dynamic immunologic process.",
"   </p>",
"   <p>",
"    Numerous case reports have identified instances of infection becoming overt in patients after long periods of time away from endemic regions for coccidioidomycosis. One patient with the acquired immunodeficiency syndrome (AIDS), for example, developed active coccidioidal disease for the first time in Spain, approximately 12 years after leaving the southwestern United States [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/11\">",
"     11",
"    </a>",
"    ]. From 1987 to 1992, 46 percent of all coccidioidal infections in patients with AIDS in the United States were diagnosed in residents of non-endemic regions [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of reactivation appears to depend upon the level of immunosuppression. One group of investigators found that severity of the infection and death was correlated with the extent of the underlying Hodgkin lymphoma in patients with this cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/1\">",
"     1",
"    </a>",
"    ]. However, in patients within the endemic regions undergoing renal replacement therapy, only 2 to 3 percent annually developed active disease, a proportion much smaller than that presumed to have been infected prior to transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/2\">",
"     2",
"    </a>",
"    ]. Recent infection rates within the endemic area appear even smaller than before [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/13\">",
"     13",
"    </a>",
"    ], possibly due in part by more targeted anti-rejection drug regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF IMMUNOSUPPRESSED PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ongoing debate about the need for treatment of the primary infection in otherwise healthy patients does not generally apply to immunosuppressed hosts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=see_link&amp;anchor=H630028667#H630028667\">",
"     \"Primary coccidioidal infection\", section on 'Uncomplicated infections'",
"    </a>",
"    .) Patients with any of the immunosuppressive conditions discussed below, who develop any evidence of an active coccidioidal infection, warrant treatment because the likelihood of complications is so high [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The selection of drugs to treat coccidioidomycosis does not differ for immunocompromised patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/16\">",
"     16",
"    </a>",
"    ]. However, since many immunosuppressed patients are receiving other drugs that may have significant interactions with triazole antifungals, especially",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , a review of all the patient's medications should be conducted prior to initiating antifungal therapy. Appropriate dose modifications should be instituted if a triazole drug is chosen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H31#H31\">",
"     \"Pharmacology of azoles\", section on 'Drug interactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While the choice of drug is similar in immunocompromised patients, the duration of therapy for coccidioidomycosis is not the same. Treatment should probably be continued indefinitely in patients with ongoing immunosuppression compared to courses of therapy up to 12 months in other patients with careful observation for relapse after cessation of treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26807?source=see_link\">",
"     \"Manifestations and treatment of extrapulmonary coccidioidomycosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Patients with HIV/AIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the development of combination antiretroviral therapy, coccidioidomycosis was recognized as a major opportunistic infection (OI) for those human immunodeficiency virus (HIV)-infected individuals who had lived or were living within the coccidioidal endemic area [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/17\">",
"     17",
"    </a>",
"    ]. While it is clear that coccidioidomycosis among HIV-infected patients can be due to reactivation of previously acquired infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/11,12\">",
"     11,12",
"    </a>",
"    ], most cases identified within the coccidioidal endemic area appear to be due to recent acquisition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cellular immune function, reflected through the peripheral blood CD4 lymphocyte count, is the most important factor in determining whether a patient with HIV infection will develop symptomatic coccidioidomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/18\">",
"     18",
"    </a>",
"    ]. A prospective study performed in the era before the advent of potent combination antiretroviral therapy demonstrated that approximately 25 percent of a cohort living in an endemic region developed symptomatic coccidioidomycosis. The main risk factor was a CD4 count &lt;250",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    or a clinical diagnosis of AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because immunosuppression is the leading risk factor for the development of symptomatic coccidioidomycosis among HIV-infected patients, the use of potent combination antiretroviral therapy, which results in immune restoration and increased CD4 cell counts, appears to have decreased the incidence of symptomatic coccidioidomycosis in this group [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/17,20\">",
"     17,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several patterns of disease have been described in HIV-infected patients. In one case-controlled study, increased severity of disease was associated with low CD4 cell counts and uncontrolled viremia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A diffuse pulmonary process is most commonly seen in the setting of advanced immunosuppression and is associated with a high mortality rate [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/6,7,21\">",
"     6,7,21",
"    </a>",
"    ]. This diffuse bilateral reticulonodular pattern may be indistinguishable from Pneumocystis jirovecii (carinii) pneumonia and may occur concomitantly with it. Associated symptoms can include dyspnea, fever and night sweats.",
"   </p>",
"   <p>",
"    In less immunocompromised patients, coccidioidomycosis presents similarly as in immunocompetent hosts. The most common presentation is focal pneumonia with cough, fever, and a localized infiltrate. Suspicion of coccidioidal pneumonia may arise if the patient has been in an endemic area, has hilar or mediastinal lymphadenopathy, peripheral eosinophilia, night sweats and fatigue, and no clinical response to treatment for community acquired pneumonia.",
"   </p>",
"   <p>",
"    Disseminated forms of coccidioidomycosis are common in the setting of HIV infection and include meningitis and lymph node and skin involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/22\">",
"     22",
"    </a>",
"    ]. However, bone and joint involvement appears to be distinctly less common among those with HIV infection.",
"   </p>",
"   <p>",
"    HIV-infected patients may also present with fever and weight loss without any clear organ involvement in association with a positive coccidioidal serology [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis is established through serologic testing, histopathological identification, and culture as it is in the noncompromised host. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13751?source=see_link\">",
"     \"Laboratory diagnosis of coccidioidomycosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Coccidioidal serologic tests appear to be less likely to be positive in patients with HIV infection than in immunocompetent hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/24\">",
"     24",
"    </a>",
"    ]. As an example, one-third of HIV-infected patients with diffuse reticulonodular pulmonary infiltrates were seronegative [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/7\">",
"     7",
"    </a>",
"    ]. Diagnosis may require identification of the fungus in respiratory secretions or other involved sites; culture results are frequently available in less than five days. Occasionally, fungus will be isolated from blood cultures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with focal pneumonia should be treated, regardless of their CD4 count, with triazole therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/25\">",
"     25",
"    </a>",
"    ] at daily doses of at least 400 mg. If itraconazole is used, dosing should be split into 200 mg twice daily to optimize absorption. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link\">",
"     \"Pharmacology of azoles\"",
"    </a>",
"    .) For patients with localized pulmonary disease who are on potent antiretroviral therapy and have a CD4 cell count above",
"    <span class=\"nowrap\">",
"     250/microL,",
"    </span>",
"    treatment for one year with subsequent discontinuation of therapy is reasonable.",
"   </p>",
"   <p>",
"    There are few published data on the management of HIV-infected patients with disseminated disease. In our clinical experience, patients with diffuse pulmonary infiltrates have a more rapid clinical response to a combination therapy approach that includes an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    formulation and a triazole antifungal agent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/22\">",
"     22",
"    </a>",
"    ]. We generally use the deoxycholate formulation, reserving liposomal amphotericin for patients with pre-existing renal insufficiency. We discontinue amphotericin after the patient has demonstrated clinical improvement, usually after a total dose of 500 to 1000 mg and subsequently continue azole therapy alone for a prolonged period beyond 12 months.",
"   </p>",
"   <p>",
"    In selecting azole therapy for localized pulmonary or disseminated disease, we prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (400 to 800 mg daily) over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    . Itraconazole is associated with multiple drug interactions, including HIV-1 protease inhibitors. Furthermore, patients with severe HIV infection may have gastric achlorhydria that could limit the gastrointestinal absorption of itraconazole. In contrast, achlorhydria does not appear to affect the absorption of fluconazole.",
"   </p>",
"   <p>",
"    Based upon data generated before the advent of potent combination antiretroviral therapy, it was recommended that all patients remain on lifelong therapy. However, this may not be necessary in patients on effective antiretroviral therapy whose peripheral blood CD4 counts are above",
"    <span class=\"nowrap\">",
"     250/microL.",
"    </span>",
"    In such cases, it may be reasonable to discontinue antifungal therapy if there is no evidence of active coccidioidal infection and there are no factors that would lead to continued therapy in an immunocompetent host.",
"   </p>",
"   <p>",
"    Coccidioidal meningitis in both immunocompetent hosts and HIV-infected patients requires lifelong therapy. This is discussed in detail elsewhere (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17271?source=see_link\">",
"     \"Coccidioidal meningitis\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the patient with HIV infection and a CD4 count less than 250",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    the most effective way to prevent the development of severe coccidioidomycosis is to institute potent combination antiretroviral therapy.",
"   </p>",
"   <p>",
"    Use of prophylactic azole antifungals is costly and is not clearly associated with a reduction of risk for disease in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/17\">",
"     17",
"    </a>",
"    ]. It is reasonable for individuals to try to avoid excessive environmental exposure within the coccidioidal endemic area. This would include staying inside during dust storms and not engaging in activities that result in exposure to local dust or desert soil. Despite such measures, the risk of acquiring coccidioidomycosis cannot be completely abrogated within the endemic area. HIV-infected patients visiting or living in these areas should be educated about these risks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Solid organ transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coccidioidomycosis has complicated the course of organ transplant recipients both inside the endemic regions and elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/2,26-29\">",
"     2,26-29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    .) Early reports reflected a high mortality rate for these patients, but mortality has decreased more recently. Possible reasons for this trend include earlier recognition of active infection or reductions in the type or level of immunosuppression that patients receive to preserve the graft [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/26\">",
"     26",
"    </a>",
"    ]. Many patients with coccidioidomycosis have been treated effectively without withdrawing their antirejection therapies.",
"   </p>",
"   <p>",
"    An important consideration for transplantation programs is to identify patients before engraftment who may be at significant risk of reactivating latent coccidioidal infection post-transplantation. In one retrospective review of all patients who had either a history of coccidioidomycosis prior to renal or cardiac transplantation or a positive pre-transplant serology, those who did not receive antifungal therapy had a high incidence of recurrent infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/30\">",
"     30",
"    </a>",
"    ]. Two of four patients who were not given antifungal drugs from the time of engraftment developed fatal recurrent infection compared to zero of five patients treated with antifungal therapy.",
"   </p>",
"   <p>",
"    These findings suggest that it may be valuable to screen transplant recipients for prior coccidioidal infection before they undergo engraftment. Since 1999, such an approach has been followed by transplantation centers within an endemic area [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/13,31\">",
"     13,31",
"    </a>",
"    ]. In patients undergoing liver, pancreas, or kidney transplantation, 44 were identified as having a history or serologic evidence of prior coccidioidal infection without current symptoms of active infection. Of these, 37 received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    following transplantation and had no evidence of reactivated infection. The remaining seven either did not receive post-operative fluconazole or were non-compliant and of these, two had evidence of reactivation. This experience demonstrates that prophylactic antifungal therapy will significantly reduce the likelihood of post-engraftment reactivation.",
"   </p>",
"   <p>",
"    Another study demonstrated that the risk of coccidioidal infection among transplant recipients who relocate to areas of high endemicity also appears low [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/32\">",
"     32",
"    </a>",
"    ]. These studies suggest that targeted prophylaxis may be effective in patients who live in endemic areas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31718?source=see_link\">",
"     \"Evaluation for infection before solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There have been several reports of coccidioidomycosis transmission associated with allogeneic solid organ transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/14,33\">",
"     14,33",
"    </a>",
"    ]. While guidelines have yet to be developed, it seems reasonable to consider screening such donors for active coccidioidomycosis prior to transplantation of their organs. An approach to prophylaxis and treatment of coccidioidomycosis in the solid organ transplantation recipient has been published [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hematologic malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hematologic malignancies are at risk for serious coccidioidal infections. It is unclear to what extent this is due to the underlying malignancy or to the chemotherapy used to treat the cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/1\">",
"     1",
"    </a>",
"    ]. However, severe illness may develop even in patients who are in remission and who have completed radiation and chemotherapy.",
"   </p>",
"   <p>",
"    A retrospective review identified 55 patients with coccidioidomycosis and underlying hematologic malignancy in a major medical center in Arizona [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/35\">",
"     35",
"    </a>",
"    ]. The most common malignancies were non-Hodgkin lymphoma and chronic lymphocytic leukemia. Pulmonary involvement was present in 95 percent of patients. Of the 16 patients who died in follow-up, 15 had active infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Glucocorticoid and immunosuppressive therapies for autoimmune diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;One review of coccidioidomycosis patients with potentially immunocompromising conditions noted that a major unifying factor was the systemic administration of glucocorticoid steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/36\">",
"     36",
"    </a>",
"    ]. However, the exact risk has not been clearly defined. Of the many patients who chronically receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    in doses of 5 to 15 mg per day for the management of chronic obstructive lung disease, very few develop disseminated coccidioidal infections. However, it is presumed that the risk is increased in patients receiving chronic therapy with higher doses.",
"   </p>",
"   <p>",
"    Other drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    for the management of rheumatologic diseases, even in the absence of corticosteroids, have been associated with disseminated coccidioidomycosis. There have also been case reports of disseminated coccidioidomycosis in patients receiving anti-tumor necrosis factor-alpha (TNF-alpha) therapies. In one report, thirteen cases of acute coccidioidomycosis were identified in patients living in a coccidioidal endemic region who received TNF-alpha inhibitor therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/3\">",
"     3",
"    </a>",
"    ]. Use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , a monoclonal antibody directed against TNF-alpha, in combination with methotrexate was associated with a five-fold increase in risk. The risk associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , a TNF-alpha receptor agonist, was much lower. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=see_link&amp;anchor=H18#H18\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections\", section on 'Coccidioidomycosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon these observations, obtaining a history of prior symptomatic coccidioidomycosis and a coccidioidal serology prior to initiating such therapy is prudent. Many experts would initiate triazole therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ) at a daily dose of 400 mg in patients with positive coccidioidal serologic tests prior to initiating anti-TNF-alpha therapy and continuing antifungal agents as long as the patient remained on such treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early reports emphasized that women first diagnosed with coccidioidomycosis during pregnancy, especially the third trimester or the peripartum period, were likely to follow a severe course [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Pregnancy was also identified to be significantly associated with dissemination in an analysis of risk factors for this outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, several population-based analyses suggest a different interpretation. In one of these studies, the outcomes of more than 47,000 pregnancies within metropolitan Tucson were reviewed; 10 patients were found to develop coccidioidomycosis, only three of which arose during or soon after the third trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/41\">",
"     41",
"    </a>",
"    ]. More than 300 such infections should have occurred during the third trimester or later, based on the assumption that two-thirds of pregnant women had not previously had coccidioidomycosis and that the annual risk of infection is three percent. That so few cases were actually detected suggests that many pregnant patients with coccidioidomycosis have sufficiently mild infection to go undiagnosed. This concept is reinforced in a second report [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/40,42\">",
"     40,42",
"    </a>",
"    ]. During an epidemic period in Kern County when the awareness of new infections of coccidioidomycosis was very high, 32 infections were identified in pregnant women; only three progressed to dissemination, and none of the patients died. Most patients were not treated and managed with supportive care.",
"   </p>",
"   <p>",
"    When therapy is deemed appropriate for coccidioidomycosis during pregnancy, the recommended drug is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    . Therapy with an azole antifungal is contraindicated because of the risk of teratogenicity, particularly during the first trimester. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link\">",
"     \"Pharmacology of azoles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CONDITIONS WITHOUT PROVEN RISK OF DISSEMINATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although experimental studies have raised the possibility of immunologic deficiencies associated with diabetes mellitus, there is little evidence that diabetic patients per se are predisposed to disseminated coccidioidomycosis. There has been a long-held belief that adult diabetics are predisposed to fibrocavitary complications and this has been corroborated by a report [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=see_link\">",
"     \"Primary coccidioidal infection\"",
"    </a>",
"    .) This study also suggested that patients with poorly controlled hyperglycemia (greater than 220",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    had a two- to threefold increased risk of dissemination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Humoral deficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experimental evidence suggests that humoral immunity is not protective against C. immitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/44\">",
"     44",
"    </a>",
"    ]. Consistent with this finding, patients with hypogammaglobulinemia from whatever cause have not been found to have unusually severe coccidioidal infections. Complement may be involved in chemotaxis of neutrophils or other leukocytes to areas of coccidioidal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/45\">",
"     45",
"    </a>",
"    ], and in patients with primary coccidioidomycosis, serum concentrations of complement components were found to be low during early coccidioidal infections [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/46\">",
"     46",
"    </a>",
"    ]. However, follow-up measurements returned to normal, suggesting that the perturbations were a consequence rather than a cause of primary infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Chronic granulomatous disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;One patient with chronic granulomatous disease (CGD) has been recognized as having coccidioidomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/47\">",
"     47",
"    </a>",
"    ]. His course was uncomplicated and did not require therapy for resolution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Bone marrow transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Very few patients undergoing bone marrow transplantation have developed coccidioidomycosis. One report described three cases from three institutions [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/48\">",
"     48",
"    </a>",
"    ]. Another report suggests good outcome even in a patient with active disease at the time of transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/49\">",
"     49",
"    </a>",
"    ]. A review of 121 consecutive patients from a single center within the endemic region identified three cases, one of whom died of disseminated coccidioidomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21848/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/19/13617?source=see_link\">",
"       \"Patient information: Valley Fever (coccidioidomycosis) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9786051\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coccidioidomycosis is usually a self-limited infection in the immunocompetent host, resulting in lifelong immunity. However, in the immunocompromised host, coccidioidomycosis can lead to severe pneumonia and disseminated disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disseminated coccidioidomycosis is most commonly characterized by skin, bone and joint lesions and meningeal involvement. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Sites of infection and histology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunocompromised patients can develop primary coccidioidomycosis through inhalation, or previously dormant sites of infection can reactivate. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Reactivation of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to the development of combination antiretroviral therapy, coccidioidomycosis was recognized as a major opportunistic infection in HIV-infected patients living in endemic areas. The incidence of coccidioidomycosis has declined with the era of potent antiretroviral therapy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Patients with HIV/AIDS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical presentation of coccidioidomycosis will depend on the level of immunosuppression. In HIV-infected patients with relatively preserved CD4 cell counts, a focal pneumonia may be seen, while patients with advanced immunosuppression may have diffuse pulmonary involvement with meningitis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other risk groups for severe coccidioidomycosis include transplant recipients and patients who have been treated with cancer chemotherapy, immunosuppressive agents, or glucocorticoids. Tumor necrosis factor (TNF)-alpha inhibitors also place patients at risk for developing severe and disseminated coccidioidomycosis. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Hematologic malignancies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/1\">",
"      Deresinski SC, Stevens DA. Coccidioidomycosis in compromised hosts. Experience at Stanford University Hospital. Medicine (Baltimore) 1975; 54:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/2\">",
"      Cohen IM, Galgiani JN, Potter D, Ogden DA. Coccidioidomycosis in renal replacement therapy. Arch Intern Med 1982; 142:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/3\">",
"      Bergstrom L, Yocum DE, Ampel NM, et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum 2004; 50:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/4\">",
"      Mertz LE, Blair JE. Coccidioidomycosis in rheumatology patients: incidence and potential risk factors. Ann N Y Acad Sci 2007; 1111:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/5\">",
"      Ampel NM, Ryan KJ, Carry PJ, et al. Fungemia due to Coccidioides immitis. An analysis of 16 episodes in 15 patients and a review of the literature. Medicine (Baltimore) 1986; 65:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/6\">",
"      Bronnimann DA, Adam RD, Galgiani JN, et al. Coccidioidomycosis in the acquired immunodeficiency syndrome. Ann Intern Med 1987; 106:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/7\">",
"      Fish DG, Ampel NM, Galgiani JN, et al. Coccidioidomycosis during human immunodeficiency virus infection. A review of 77 patients. Medicine (Baltimore) 1990; 69:384.",
"     </a>",
"    </li>",
"    <li>",
"     Eaton ME, Muth WE, Aguirre ML, Galgiani J. Gastrointestinal coccidioidomycosis. In: Coccidioidomycosis. Proceedings of the Fifth International Conference, Einstein HE, Catanzaro A (Eds), National Foundation for Infectious Diseases, Washington, DC 1996. p.359.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/9\">",
"      Graham AR, Sobonya RE, Bronnimann DA, Galgiani JN. Quantitative pathology of coccidioidomycosis in acquired immunodeficiency syndrome. Hum Pathol 1988; 19:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/10\">",
"      Forseth J, Rohwedder JJ, Levine BE, Saubolle MA. Experience with needle biopsy for coccidioidal lung nodules. Arch Intern Med 1986; 146:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/11\">",
"      Hern&aacute;ndez JL, Echevarr&iacute;a S, Garc&iacute;a-Valtuille A, et al. Atypical coccidioidomycosis in an AIDS patient successfully treated with fluconazole. Eur J Clin Microbiol Infect Dis 1997; 16:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/12\">",
"      Jones JL, Fleming PL, Ciesielski CA, et al. Coccidioidomycosis among persons with AIDS in the United States. J Infect Dis 1995; 171:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/13\">",
"      Blair JE. Coccidioidomycosis in patients who have undergone transplantation. Ann N Y Acad Sci 2007; 1111:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/14\">",
"      Miller MB, Hendren R, Gilligan PH. Posttransplantation disseminated coccidioidomycosis acquired from donor lungs. J Clin Microbiol 2004; 42:2347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/15\">",
"      Galgiani JN, Ampel NM. Coccidioidomycosis in human immunodeficiency virus-infected patients. J Infect Dis 1990; 162:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/16\">",
"      Galgiani JN, Ampel NM, Catanzaro A, et al. Practice guideline for the treatment of coccidioidomycosis. Infectious Diseases Society of America. Clin Infect Dis 2000; 30:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/17\">",
"      Woods CW, McRill C, Plikaytis BD, et al. Coccidioidomycosis in human immunodeficiency virus-infected persons in Arizona, 1994-1997: incidence, risk factors, and prevention. J Infect Dis 2000; 181:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/18\">",
"      Ampel NM. Delayed-type hypersensitivity, in vitro T-cell responsiveness and risk of active coccidioidomycosis among HIV-infected patients living in the coccidioidal endemic area. Med Mycol 1999; 37:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/19\">",
"      Ampel NM, Dols CL, Galgiani JN. Coccidioidomycosis during human immunodeficiency virus infection: results of a prospective study in a coccidioidal endemic area. Am J Med 1993; 94:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/20\">",
"      Masannat FY, Ampel NM. Coccidioidomycosis in patients with HIV-1 infection in the era of potent antiretroviral therapy. Clin Infect Dis 2010; 50:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/21\">",
"      Singh VR, Smith DK, Lawerence J, et al. Coccidioidomycosis in patients infected with human immunodeficiency virus: review of 91 cases at a single institution. Clin Infect Dis 1996; 23:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/22\">",
"      Ampel NM. Coccidioidomycosis in persons infected with HIV type 1. Clin Infect Dis 2005; 41:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/23\">",
"      Arguinchona HL, Ampel NM, Dols CL, et al. Persistent coccidioidal seropositivity without clinical evidence of active coccidioidomycosis in patients infected with human immunodeficiency virus. Clin Infect Dis 1995; 20:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/24\">",
"      Antoniskis D, Larsen RA, Akil B, et al. Seronegative disseminated coccidioidomycosis in patients with HIV infection. AIDS 1990; 4:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/25\">",
"      Galgiani JN, Catanzaro A, Cloud GA, et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group. Ann Intern Med 2000; 133:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/26\">",
"      Blair JE, Logan JL. Coccidioidomycosis in solid organ transplantation. Clin Infect Dis 2001; 33:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/27\">",
"      Hall KA, Sethi GK, Rosado LJ, et al. Coccidioidomycosis and heart transplantation. J Heart Lung Transplant 1993; 12:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/28\">",
"      Logan JL, Blair JE, Galgiani JN. Coccidioidomycosis complicating solid organ transplantation. Semin Respir Infect 2001; 16:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/29\">",
"      Holt CD, Winston DJ, Kubak B, et al. Coccidioidomycosis in liver transplant patients. Clin Infect Dis 1997; 24:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/30\">",
"      Hall KA, Copeland JG, Zukoski CF, et al. Markers of coccidioidomycosis before cardiac or renal transplantation and the risk of recurrent infection. Transplantation 1993; 55:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/31\">",
"      Blair JE, Kusne S, Carey EJ, Heilman RL. The prevention of recrudescent coccidioidomycosis after solid organ transplantation. Transplantation 2007; 83:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/32\">",
"      Blair JE, Douglas DD. Coccidioidomycosis in liver transplant recipients relocating to an endemic area. Dig Dis Sci 2004; 49:1981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/33\">",
"      Wright PW, Pappagianis D, Wilson M, et al. Donor-related coccidioidomycosis in organ transplant recipients. Clin Infect Dis 2003; 37:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/34\">",
"      Blair JE. Approach to the solid organ transplant patient with latent infection and disease caused by Coccidioides species. Curr Opin Infect Dis 2008; 21:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/35\">",
"      Blair JE, Smilack JD, Caples SM. Coccidioidomycosis in patients with hematologic malignancies. Arch Intern Med 2005; 165:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/36\">",
"      Rutala PJ, Smith JW. Coccidioidomycosis in potentially compromised hosts: the effect of immunosuppressive therapy in dissemination. Am J Med Sci 1978; 275:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/37\">",
"      Peterson CM, Schuppert K, Kelly PC, Pappagianis D. Coccidioidomycosis and pregnancy. Obstet Gynecol Surv 1993; 48:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/38\">",
"      McCoy MJ, Ellenberg JF, Killam AP. Coccidioidomycosis complicating pregnancy. Am J Obstet Gynecol 1980; 137:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/39\">",
"      Harris RE. Coccidioidomycosis complicating pregnancy. Report of 3 cases and review of the literature. Obstet Gynecol 1966; 28:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/40\">",
"      Rosenstein NE, Emery KW, Werner SB, et al. Risk factors for severe pulmonary and disseminated coccidioidomycosis: Kern County, California, 1995-1996. Clin Infect Dis 2001; 32:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/41\">",
"      Wack EE, Ampel NM, Galgiani JN, Bronnimann DA. Coccidioidomycosis during pregnancy. An analysis of ten cases among 47,120 pregnancies. Chest 1988; 94:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/42\">",
"      Caldwell JW, Arsura EL, Kilgore WB, et al. Coccidioidomycosis in pregnancy during an epidemic in California. Obstet Gynecol 2000; 95:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/43\">",
"      Santelli AC, Blair JE, Roust LR. Coccidioidomycosis in patients with diabetes mellitus. Am J Med 2006; 119:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/44\">",
"      Beaman LV, Pappagianis D, Benjamini E. Mechanisms of resistance to infection with Coccidioides immitis in mice. Infect Immun 1979; 23:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/45\">",
"      Galgiani JN, Isenberg RA, Stevens DA. Chemotaxigenic activity of extracts from the mycelial and spherule phases of Coccidioides immitis for human polymorphonuclear leukocytes. Infect Immun 1978; 21:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/46\">",
"      Galgiani JN, Yam P, Petz LD, et al. Complement activation by Coccidioides immitis: in vitro and clinical studies. Infect Immun 1980; 28:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/47\">",
"      Galgiani JN. Inhibition of different phases of Coccidioides immitis by human neutrophils or hydrogen peroxide. J Infect Dis 1986; 153:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/48\">",
"      Riley DK, Galgiani JN, O'Donnell MR, et al. Coccidioidomycosis in bone marrow transplant recipients. Transplantation 1993; 56:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/49\">",
"      Schriber J, Almond H, Alvarnas J, Sarkadee-Adoo C. Successful allogeneic bone marrow transplantation in a patient with active Coccidioidomycosis. Bone Marrow Transplant 2005; 35:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21848/abstract/50\">",
"      Glenn TJ, Blair JE, Adams RH. Coccidioidomycosis in hematopoietic stem cell transplant recipients. Med Mycol 2005; 43:705.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2418 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-294E67EF58-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_21_21848=[""].join("\n");
var outline_f21_21_21848=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9786051\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFECT ON DISEASE EXPRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Increased disease severity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Sites of infection and histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Reactivation of infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MANAGEMENT OF IMMUNOSUPPRESSED PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Patients with HIV/AIDS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hematologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Glucocorticoid and immunosuppressive therapies for autoimmune diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CONDITIONS WITHOUT PROVEN RISK OF DISSEMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Humoral deficiencies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Chronic granulomatous disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Bone marrow transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9786051\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2418\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2418|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/62/40930\" title=\"diagnostic image 1\">",
"      Disseminated coccidioidomycosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17271?source=related_link\">",
"      Coccidioidal meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31718?source=related_link\">",
"      Evaluation for infection before solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=related_link\">",
"      Infection in the solid organ transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13751?source=related_link\">",
"      Laboratory diagnosis of coccidioidomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/51/39734?source=related_link\">",
"      Management of pulmonary sequelae and complications of coccidioidomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26807?source=related_link\">",
"      Manifestations and treatment of extrapulmonary coccidioidomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/19/13617?source=related_link\">",
"      Patient information: Valley Fever (coccidioidomycosis) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=related_link\">",
"      Primary coccidioidal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_21_21849="Invasive cervical cancer: Staging and evaluation of lymph nodes";
var content_f21_21_21849=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Invasive cervical cancer: Staging and evaluation of lymph nodes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/21/21849/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/21/21849/contributors\">",
"     Michael Frumovitz, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/21/21849/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/21/21849/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/21/21849/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/21/21849/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/21/21849/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/21/21849/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer of the uterine cervix is staged using a clinical, rather than a surgical staging system, which is the approach used for other gynecologic tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Surgical staging is potentially more accurate [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/3\">",
"     3",
"    </a>",
"    ]. However, the International Federation of Gynecology and Obstetrics has determined that clinical staging is preferable for several reasons: it is more accessible for low resource settings, in which cervical cancer remains the most common malignancy among women; it may be better for assessing locally advanced disease (ie, tumor size, vaginal and parametrial involvement); and it avoids surgery in women who are not candidates for surgical treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tumor stage is determined at the time of primary diagnosis of cervical cancer and is not altered, even upon recurrence. This convention also applies to other gynecologic cancers. Accurate pretreatment staging of cervical cancer is critical, as it determines therapy (ie, surgery, chemoradiation, chemotherapy alone) and prognosis (",
"    <a class=\"graphic graphic_table graphicRef64747 \" href=\"UTD.htm?27/28/28108\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The staging and evaluation of lymph nodes for cervical cancer will be reviewed here. Cervical cancer screening and prevention, epidemiology, risk factors, clinical manifestations, diagnosis, and treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link\">",
"     \"Screening for cervical cancer: Rationale and recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=see_link\">",
"     \"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link\">",
"     \"Management of early stage cervical cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=see_link\">",
"     \"Management of locally advanced cervical cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30762?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STAGING SYSTEMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of cervical cancer is made based upon histologic evaluation of a cervical biopsy. After histologic confirmation, the extent of disease is determined. Two parallel staging systems are available, both of which use clinical rather than surgical criteria to assign disease stage (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Staging procedure'",
"    </a>",
"    below). The corresponding stages of the two systems are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef79282 \" href=\"UTD.htm?33/6/33902\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     FIGO system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Federation of Gynecology and Obstetrics (FIGO) collaborated with the International Union Against Cancer (IUCC) to formulate the most recent version of the FIGO system for cervical cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The FIGO staging system is largely based upon physical examination and a limited number of endoscopic diagnostic procedures and imaging studies (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Staging procedure'",
"    </a>",
"    below). The FIGO system is used more commonly than the TNM system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     TNM system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Joint Committee on Cancer and the IUCC created a TNM classification system that is parallel to the FIGO system. Clinical TNM staging is based upon the same staging procedure as FIGO staging. The \"T\" stages correspond to the FIGO stages with the exception of carcinoma in situ. The TNM system designates this Tis, but FIGO no longer includes stage 0 (",
"    <a class=\"graphic graphic_table graphicRef79282 \" href=\"UTD.htm?33/6/33902\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The TNM system also includes a pathologic staging system (pTNM) to be used for women who undergo surgical treatment or in whom cervical cancer is discovered incidentally after hysterectomy. The AJCC advises that the results of the pathologic evaluation should not be allowed to change the clinical stage, but be recorded separately as the pathologic stage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     STAGING PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard staging procedure International Federation of Gynecology and Obstetrics (FIGO) guidelines allow the following examinations for establishing the stage of cervical cancer, but it is not mandatory to perform all of these tests on every patient [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physical examination",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Pelvic examination &ndash; speculum, bimanual, and rectovaginal examination for palpation and inspection of the primary tumor, uterus, vagina, and parametria",
"     </li>",
"     <li>",
"      Examination for distant metastases &ndash; palpation of groin and supraclavicular lymph nodes; examination of the right upper quadrant",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cervical biopsy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Colposcopy with directed cervical biopsy",
"     </li>",
"     <li>",
"      Endocervical curettage",
"     </li>",
"     <li>",
"      Conization",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endoscopy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hysteroscopy",
"     </li>",
"     <li>",
"      Cystoscopy",
"     </li>",
"     <li>",
"      Proctoscopy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Imaging studies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Intravenous pyelogram (IVP) &ndash; evaluation for urinary tract obstruction; in many centers computed tomography or magnetic resonance imaging is used instead.",
"     </li>",
"     <li>",
"      Imaging with a plain chest radiograph and radiograph of the skeleton &ndash; evaluation for metastases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The FIGO staging system is largely based upon physical examination. Thus, a good pelvic examination by an experienced examiner is of critical importance. Rarely does it need to be performed under anesthesia.",
"   </p>",
"   <p>",
"    Cervical cancer spreads locally by extension to the uterine corpus, vagina, and parametria. Thus, the cervix and entire vagina should be inspected and palpated to identify overt tumors or subepithelial vaginal extension. Vaginal extension is diagnosed with visual inspection, biopsy is not typically required. Tumor size and parametrial involvement are best assessed by rectovaginal examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=see_link&amp;anchor=H1087317#H1087317\">",
"     \"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis\", section on 'Routes of spread'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cervical biopsy may have been performed as part of an initial evaluation or along with the staging procedure, depending on the level of suspicion of malignancy. The approach to cervical biopsy (eg, colposcopy with directed biopsy or conization) differs depending upon the patient&rsquo;s presentation, findings on pelvic examination, and the patient&rsquo;s access to health care. Usually, once a biopsy confirms invasive disease, repeat biopsy or cervical conization procedure is not necessary unless the conization is part of treatment (eg, a stage IA1 cancer being treated definitively with cone biopsy). Approaches to cervical biopsy for varying presentations (ie, visible lesion, abnormal cytology) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=see_link&amp;anchor=H1087497#H1087497\">",
"     \"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis\", section on 'Cervical biopsy and colposcopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hysteroscopy, cystoscopy, and proctoscopy can be used to assess adjacent areas. Suspicious lesions should be confirmed by biopsy.",
"   </p>",
"   <p>",
"    The limitations of FIGO clinical staging are well appreciated. Parametrial and sidewall invasion, as well as metastases to lymph nodes, can be difficult to assess accurately using the tests listed above. This leads to understaging of some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Clinical staging appears to perform best for microscopic or late stage disease, but less well for the stages that depend largely upon assessment of tumor size or local spread [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/8\">",
"     8",
"    </a>",
"    ]. Based upon international data from over 13,000 women with cervical cancer, the correlation between clinical staging and surgicopathologic findings reached 90 percent or higher only for stage IA1 (microscopic disease) and stages IIIB and IVA (tumor extends to pelvic sidewall, hydronephrosis, or",
"    <span class=\"nowrap\">",
"     bladder/rectal",
"    </span>",
"    invasion) (",
"    <a class=\"graphic graphic_table graphicRef79282 \" href=\"UTD.htm?33/6/33902\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/9\">",
"     9",
"    </a>",
"    ]. For other stages, the correlation between clinical and surgical stage ranged from 66 to 83 percent.",
"   </p>",
"   <p>",
"    For these reasons, additional testing modalities are used to evaluate women with cervical cancer, where available, and the results of these tests are used for planning treatment; FIGO sanctioned studies alone are used in the minority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/8,10\">",
"     8,10",
"    </a>",
"    ]. However, the majority of oncologists still report their data based upon the FIGO system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     FURTHER EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical staging system for cervical cancer is limited to the specified set of examinations and does not assess the full extent of disease in all women. In particular, evaluation with imaging studies, surgical procedures, and laboratory evaluation are routinely used to detect the presence and impact of lymph node metastases and distant metastases.",
"   </p>",
"   <p>",
"    The results of these examinations",
"    <strong>",
"     do not",
"    </strong>",
"    alter the International Federation of Gynecology and Obstetrics (FIGO) stage [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The only exception to this is the assessment of hydronephrosis or hydroureter, which is now commonly assessed with imaging studies other than the modality specified by FIGO (ie, intravenous pyelography) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The information provided by additional examinations is important in making treatment decisions. An overview of the typical treatment of cervical cancer is helpful to inform this discussion (",
"    <a class=\"graphic graphic_table graphicRef79282 \" href=\"UTD.htm?33/6/33902\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Selected women with microscopic disease (stage IA1) may be treated with extrafascial hysterectomy, cone biopsy, or simple trachelectomy.",
"     </li>",
"     <li>",
"      Women with a tumor that is confined to the cervix, uterus, upper third of the vagina (stage IA2, IB1, IIA1) that is nonbulky (&le;4 cm) and who do not have lymph node metastases are candidates for radical hysterectomy.",
"     </li>",
"     <li>",
"      Women with local extension (eg, to the low two-thirds of the vagina, parametrium, or bladder) that is bulky (stage IB2, IIA2 to IVA) or with lymph node metastases are generally treated with chemoradiation. Assessment of lymph nodes helps to design the radiation fields (ie, pelvic radiation versus extended field radiation).",
"     </li>",
"     <li>",
"      Those with widely metastatic disease (eg, carcinomatosis or lung metastases) (stage IVB) are typically treated with full dose chemotherapy alone. Palliative radiation therapy may be used to reduce vaginal bleeding or pain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment of cervical cancer is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link&amp;anchor=H546745501#H546745501\">",
"     \"Management of early stage cervical cancer\", section on 'Adjuvant therapy indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The choice of imaging studies, surgical evaluation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    laboratory testing must be coordinated to gain the most clinical information with the least number of procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10161218\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10308919\">",
"    <span class=\"h3\">",
"     Clinical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Practice patterns vary regarding the choice of post-staging imaging studies.",
"   </p>",
"   <p>",
"    The evidence regarding the performance of specific imaging modalities is reviewed in detail in the sections that follow. In our practice, we use the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women who are candidates for radical hysterectomy (stages IA2 and IB1):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We assess the tumor size and vaginal and parametrial involvement by clinical examination alone. If there is uncertainty about tumor size",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      local spread following the clinical examination, some clinicians evaluate the patient with pelvic magnetic resonance imaging (MRI).",
"     </li>",
"     <li>",
"      We order preoperative",
"      <span class=\"nowrap\">",
"       abdominal/pelvic",
"      </span>",
"      computed tomography (CT) to exclude obvious lymph node metastases and distant metastasis. If the nodes appear benign, we proceed with surgery. If the CT findings are suspicious for lymph node metastases, there are two commonly used options for further evaluation: (1) in our practice, we refer for a CT- or ultrasound-guided node biopsy or (2) other clinicians commonly use positron emission tomography (PET) for further evaluation. &nbsp;",
"     </li>",
"     <li>",
"      For women with lymph node metastases on imaging-guided biopsy or PET, some clinicians treat based upon these findings and others perform laparoscopic pelvic and paraaortic lymph node dissection to debulk enlarged nodes and provide further information to determine the radiation fields. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Surgical evaluation of lymph nodes'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with locally advanced disease (stages IB2 to IVA) for whom primary chemoradiation is planned:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Prior to treatment, we obtain a",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      to evaluate extent of disease with particular attention to lymph node metastases to provide information to design radiation fields. If the",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      shows widely metastatic disease, we treat with full dose chemotherapy rather than chemoradiation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Tumor size and local spread",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is controversial whether imaging studies are more useful than clinical examination alone to assess tumor size and local spread in women with cervical cancer. If imaging is used, MRI is the modality of choice.",
"   </p>",
"   <p>",
"    For women who are surgical candidates based upon clinical staging, some data suggest that tumor size can be determined more effectively with MRI than clinical examination. As an example, a prospective study included 208 women, most with stage IB disease, who underwent MRI and CT prior to surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/14\">",
"     14",
"    </a>",
"    ]. MRI correlated more closely with surgicopathologic findings than CT or physical examination. All three modalities overestimated tumor size. This is an important observation, as overestimation of tumor size in surgical candidates likely would not change treatment or prognosis, while underestimation of size would potentially triage a patient to surgical excision when chemoradiation would be the best option.",
"   </p>",
"   <p>",
"    Determining the presence of parametrial spread is also of critical importance for determining whether patients are candidates for surgical treatment. Data conflict regarding whether imaging studies are better able to detect parametrial spread than clinical staging [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/8,14-17\">",
"     8,14-17",
"    </a>",
"    ]. Imaging studies performed better than clinical staging in one study, a prospective multicenter study of 172 women with cervical cancer who were clinically staged as IB or higher underwent CT and MRI prior to surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/8\">",
"     8",
"    </a>",
"    ]. Detection of stage IIB or higher was poor for all approaches, but imaging studies performed better than clinical staging: clinical staging (sensitivity: 29 percent and specificity: 99 percent); CT (42 and 82 percent); and MRI (53 and 74 percent). In contrast, a retrospective study found clinical staging to be superior to CT and MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/17\">",
"     17",
"    </a>",
"    ]. In that study, the sensitivity and specificity for detection of parametrial involvement (stage IIB) was: clinical staging (sensitivity: 66 percent and specificity: 81 percent); CT (43 and 71 percent); and MRI (52 and 63 percent).",
"   </p>",
"   <p>",
"    If an imaging study is used for parametrial assessment, we suggest MRI. MRI was found to be superior to CT for evaluation of parametrial involvement in a meta-analysis of 57 studies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. There are few data regarding the use of",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    for the evaluation of tumor size or local spread in cervical cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/20\">",
"     20",
"    </a>",
"    ]. Further study is required.",
"   </p>",
"   <p>",
"    In locally advanced cervical cancer (stages IB2-IVA), correlation of tumor size by physical examination with imaging studies is difficult to estimate since those patients typically undergo definitive chemoradiation therapy, making pathologic examination and measurement of true tumor size impossible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Lymph node metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical cancer may spread to the pelvic or paraortic lymph nodes, as well as more distal nodes. The presence of lymph node involvement is associated with a worse prognosis and impacts decisions regarding the radiotherapy field [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=see_link&amp;anchor=H1087317#H1087317\">",
"     \"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis\", section on 'Routes of spread'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=see_link&amp;anchor=H25#H25\">",
"     \"Management of locally advanced cervical cancer\", section on 'Prognosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link&amp;anchor=H618915858#H618915858\">",
"     \"Management of early stage cervical cancer\", section on 'Treatment of high-risk disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Historically, surgery with lymphadenectomy was required to evaluate for lymph node metastases. Currently, options for evaluating for lymph node metastases include lymph node dissection, imaging studies, or both.",
"   </p>",
"   <p>",
"    Initial evaluation of lymph nodes is commonly performed with CT to minimize expense, but PET and",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    are the imaging modalities used to provide information for treatment decisions. These studies have largely replaced MRI and lymphangiography [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/22-26\">",
"     22-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    imaging is a technique in which both PET and CT are performed sequentially during a single visit on a hybrid",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scanner. The PET and CT images are then coregistered using fusion software, enabling the physiologic data obtained on PET to be localized according to the anatomic CT images. When",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    is performed, a low radiation dose CT without contrast is typically used to keep the radiation dose as low as possible and to limit adverse events. A higher resolution CT requires a higher dose of radiation and intravenous contrast. &nbsp;",
"   </p>",
"   <p>",
"    The superiority of PET to other imaging modalities was illustrated in a meta-analysis of 72 studies including 5042 women with cervical cancer that found the following sensitivities and specificities for the detection of lymph node metastases: PET (sensitivity: 75 and specificity: 98 percent); MRI (56 and 93 percent); and CT (58 and 92 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/27\">",
"     27",
"    </a>",
"    ]. Integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    may be more sensitive than PET alone for detection of nodal metastases, particularly for pelvic lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/28-30\">",
"     28-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there appear to be limitations to imaging with PET, depending upon nodal site and disease stage. PET appears to perform better for the detection of positive paraaortic nodes than pelvic nodes. In a literature review that included 15 studies of women with cervical cancer, pooled estimates were higher for the sensitivity of PET for involvement of pelvic (sensitivity: 79 percent and specificity: 99 percent) than paraaortic (84 and 95 percent) nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some data have raised concern that in locally advanced cervical cancer,",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    may have a higher false-negative rate for detecting paraaortic lymph node spread than previously appreciated [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. As an example, a study in 60 patients with stage IB2 to IVA disease found that 12 percent of those with no finding of positive paraaortic nodes on",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    findings had pathologically positive paraaortic nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/32\">",
"     32",
"    </a>",
"    ]. A subset of patients with",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    findings of positive pelvic and negative paraaortic negative nodes had an even higher rate of pathologically positive paraaortic disease (22 percent). In a separate study of",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    and pathologic analysis of paraaortic nodes, patients with PET positive pelvic and negative paraaortic negative nodes had a similarly high unrecognized disease to paraaortic nodes (24 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10161497\">",
"    <span class=\"h3\">",
"     Upper urinary tract involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor extension to the bladder and ureter may result in hydronephrosis and, ultimately, in nonfunctioning kidney in women with cervical cancer. The urinary tract is imaged in all patients with more than a microscopic tumor. While intravenous pyelography (IVP) is the examination included in the guidelines for clinical staging, MRI and CT urography are typically used where available [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/1\">",
"     1",
"    </a>",
"    ]. In low resource settings, IVP is still commonly used.",
"   </p>",
"   <p>",
"    Evaluation of ureteral obstruction is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=see_link\">",
"     \"Diagnosis of urinary tract obstruction and hydronephrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Surgical evaluation of lymph nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women treated with radical hysterectomy for cervical cancer also undergo assessment of pelvic and paraaortic lymph nodes. In addition, lymph node sampling is performed in some women treated with primary chemoradiation. Although the finding of positive lymph nodes does not alter the FIGO stage (",
"    <a class=\"graphic graphic_table graphicRef79282 \" href=\"UTD.htm?33/6/33902\">",
"     table 2",
"    </a>",
"    ), surgicopathologic results impacts treatment planning in up to 43 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sentinel lymph node biopsy is currently investigational [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4844274\">",
"    <span class=\"h3\">",
"     Lymph node dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymph node dissection debulks enlarged nodes, which may have a therapeutic benefit, and provides information for treatment planning (to individualize the radiotherapy field) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link&amp;anchor=H546745501#H546745501\">",
"     \"Management of early stage cervical cancer\", section on 'Adjuvant therapy indications'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    The necessity for and extent of lymphadenectomy (pelvic, paraaortic) depends upon disease stage and imaging findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of lymph node metastases with stage IA1 squamous cell cervical cancer is so small (1 percent or less) that lymphadenectomy is not performed unless there is lymphovascular space invasion, which is also rare at this early stage [",
"      <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/40\">",
"       40",
"      </a>",
"      ]. This is true for both squamous cell carcinoma and adenocarcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For stage IA2 disease or microscopic IB1 disease (nonvisible, &gt;5 mm in depth and &le;4 cm in greatest dimension), the risk of nodal metastasis is 2 to 8 percent and pelvic lymphadenectomy alone is generally sufficient since the risk for paraaortic nodal metastases is quite small [",
"      <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/13,40,42,43\">",
"       13,40,42,43",
"      </a>",
"      ]. However, if pretreatment imaging shows positive paraaortic nodes or if pelvic nodes that are enlarged or fixed are encountered at surgery, frozen section should be performed. If metastases are confirmed, paraaortic lymphadenectomy should be performed as well. &nbsp;",
"     </li>",
"     <li>",
"      For macroscopic stage IB1 and IIA1 tumors, a complete pelvic lymphadenectomy should be performed at time of hysterectomy. Paraaortic lymphadenectomy is performed at the surgeon&rsquo;s discretion and when pelvic lymph nodes are enlarged or fixed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14730?source=see_link&amp;anchor=H15#H15\">",
"       \"Radical hysterectomy\", section on 'Paraaortic node sampling'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14730?source=see_link&amp;anchor=H16#H16\">",
"       \"Radical hysterectomy\", section on 'Pelvic lymphadenectomy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    According to the Gynecologic Oncology Surgical Procedures Manual, pelvic node dissection includes removal of nodal tissue from the distal one-half of each common iliac artery, the anterior and medial aspect of the proximal half of the external iliac artery and vein, and the distal half of the obturator fat pad anterior to the obturator nerve (",
"    <a class=\"graphic graphic_figure graphicRef52298 \" href=\"UTD.htm?26/50/27425\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef75242 \" href=\"UTD.htm?37/44/38596\">",
"     figure 2",
"    </a>",
"    ). Some data suggest that removal of the circumflex iliac nodes to the distal external iliac nodes increases the risk of lymphedema [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Paraaortic node dissection consists of resection of nodal tissue over the distal vena cava from the level of the inferior mesenteric artery to the mid right common iliac artery and between the aorta and the left ureter from the inferior mesenteric artery to the left mid common iliac artery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/45\">",
"     45",
"    </a>",
"    ]. Some experts extend the paraaortic lymph node dissection (LND) superiorly to the level of the renal veins [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <br/>",
"    The evaluation procedure can be performed via laparotomy or laparoscopy through a transperitoneal or extraperitoneal approach [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]. Extraperitoneal and laparoscopic approaches to staging (including extraperitoneal laparoscopic [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/49\">",
"     49",
"    </a>",
"    ]) are associated with reduced morbidity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4455?source=see_link\">",
"     \"Laparoscopic pelvic and paraaortic lymphadenectomy in gynecologic cancers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potential surgical complications of pelvic and paraaortic lymphadenectomy include vascular damage, ureteral injury, infection, fistula formation,",
"    <span class=\"nowrap\">",
"     lymphocyst/lymphedema,",
"    </span>",
"    bowel obstruction, and thrombophlebitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4844282\">",
"    <span class=\"h3\">",
"     Sentinel lymph node biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sentinel lymph node biopsy for women with cervical cancer appears promising, but is still investigational [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/51\">",
"     51",
"    </a>",
"    ]. A literature review including 831 women who underwent lymphatic mapping and sentinel node detection as part of their cervical cancer therapy reported that a sentinel node was identified in 90 percent of cases with an overall sensitivity for metastatic disease of 92 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pathology evaluation with ultrastaging is typically used for sentinel nodes, and this may result in increased identification of metastatic lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/53\">",
"     53",
"    </a>",
"    ]. However, the importance of micrometastatic disease or isolated tumor cells in sentinel nodes remains to be established.",
"   </p>",
"   <p>",
"    Sentinel lymph node biopsy appears to perform better than imaging studies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/37\">",
"     37",
"    </a>",
"    ]. This was illustrated in a meta-analysis of 72 studies including 5042 women with cervical cancer that evaluated several approaches, and found that the sensitivity and specificity for the detection of lymph node metastases for various approaches were: sentinel node biopsy (sensitivity: 91 percent and specificity: 100 percent); PET (75 and 98 percent); MRI (56 and 93 percent); and CT (58 and 92 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3481633\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3481640\">",
"    <span class=\"h3\">",
"     Routine evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with cervical cancer should have a complete blood count, liver and renal function tests, and urinalysis to determine systemic effects and the impact of potential metastatic disease. In addition, they should have routine preoperative or pretreatment testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=see_link&amp;anchor=H10#H10\">",
"     \"Preoperative medical evaluation of the healthy patient\", section on 'Laboratory evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3481647\">",
"    <span class=\"h3\">",
"     Tumor markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of tumor markers for monitoring therapy or detecting recurrence in cervical cancer is investigational.",
"   </p>",
"   <p>",
"    A number of serum markers have been investigated for their utility in assessing prognosis, monitoring response to therapy, and detecting recurrence; none has achieved widespread acceptance. The most commonly used are serum squamous cell carcinoma (SCC) antigen, tissue polypeptide antigen, CEA, CA-125, and CYFRA 21-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/54-69\">",
"     54-69",
"    </a>",
"    ]. Many of these markers are elevated in a significant proportion of patients with more advanced stage disease, and they correlate with disease activity. CA-125 levels are elevated in only 13 to 21 percent of women with cervical squamous cell cancer, but may be a better tumor marker for those with adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least some data suggest that elevated preoperative serum levels of SCC antigen may be a helpful predictor of the need for postoperative radiation therapy (which is typically reserved for positive or close resection margins, positive lymph nodes, microscopic parametrial involvement or large tumors with deep cervical stromal invasion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lymphovascular space involvement) in patients who undergo surgery for stage",
"    <span class=\"nowrap\">",
"     IB/IIA",
"    </span>",
"    disease. This was illustrated in a cohort study of 337 women with surgically treated FIGO stage",
"    <span class=\"nowrap\">",
"     IB/IIA",
"    </span>",
"    cervical cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/70\">",
"     70",
"    </a>",
"    ]. Compared to women with a normal preoperative marker level, elevated SCC antigen levels (&gt;1.9",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    were associated with a significantly higher likelihood of needing postoperative radiation therapy both for stage IB1 (57 versus 16 percent) and",
"    <span class=\"nowrap\">",
"     IB2/IIA",
"    </span>",
"    disease (74 versus 29 percent). The potential clinical utility of this finding is in the ability to identify preoperatively most women who would likely require trimodality treatment (ie, surgery and chemoradiotherapy) so that they could be considered for primary chemoradiotherapy rather than surgery. The disadvantage is that 43 percent of women identified for primary chemoradiotherapy might have been treated by surgery alone and avoided the long-term morbidity of radiation therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=see_link&amp;anchor=H2#H2\">",
"     \"Management of locally advanced cervical cancer\", section on 'Definition of locally advanced stage cervical cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, in other mostly small reports using varying cut-off levels, the serum SCC antigen level did not accurately predict lymph node or parametrial involvement, and there are conflicting reports as to its independent prognostic significance [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21849/abstract/56,58,59,65\">",
"     56,58,59,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is also unclear whether routine serial monitoring of any of these markers adds significantly to postoperative clinical or radiographic monitoring for recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/32/28163?source=see_link\">",
"       \"Patient information: Cervical cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30436?source=see_link\">",
"       \"Patient information: Fertility preservation in women with early stage cervical cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/4/15429?source=see_link\">",
"       \"Patient information: Cervical cancer treatment; early stage cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cervical cancer is clinically staged according to the International Federation of Gynecologists and Obstetricians (FIGO) system (",
"      <a class=\"graphic graphic_table graphicRef79282 \" href=\"UTD.htm?33/6/33902\">",
"       table 2",
"      </a>",
"      ). This system only allows the use of readily available techniques, such as physical examination, biopsy, chest x-ray, cystoscopy, proctoscopy, and intravenous pyelography (IVP). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Staging procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Magnetic resonance imaging (MRI) urography and computed tomography urography are typically used in place of IVP, where available. In low resource settings, IVP is still commonly used. (See",
"      <a class=\"local\" href=\"#H10161497\">",
"       'Upper urinary tract involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tumor size and local spread are important factors in planning cervical cancer treatment, particularly in determining which women are candidates for primary surgical treatment. Understaging may result in unnecessary surgery in a woman who is better treated with primary chemoradiation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Tumor size and local spread'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of imaging studies to assess tumor size and local spread is controversial. If imaging is used, we suggest MRI rather than CT or positron emission tomography (PET). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Tumor size and local spread'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cervical cancer may spread to the pelvic or paraortic lymph nodes, as well as more distal nodes. The presence of lymph node involvement does not alter the FIGO stage, but it is associated with a worse prognosis and impacts decisions regarding the radiotherapy field. Options for evaluating for lymph node metastases include lymph node dissection, imaging studies, or both. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Lymph node metastases'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Surgical evaluation of lymph nodes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who are candidates for radical hysterectomy (stages IA2 and IB1), we suggest evaluation of the lymph nodes with imaging studies prior to surgery. We use CT for evaluation of nodes in preoperative patients. Suspicious findings can be further evaluated with an imaging-guided biopsy, lymphadenectomy, or PET. (See",
"      <a class=\"local\" href=\"#H10161218\">",
"       'Imaging studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with locally advanced disease (stages IB2 to IVA) for whom primary chemoradiation is planned, we suggest evaluation of the lymph nodes with",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      rather than CT alone or MRI. Information regarding lymph node involvement is used to design radiation fields. (See",
"      <a class=\"local\" href=\"#H10161218\">",
"       'Imaging studies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Lymph node metastases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women treated with radical hysterectomy also undergo pelvic lymphadenectomy; paraaortic lymph node dissection is performed is some women, depending upon patient characteristics and surgeon preference. Lymphadenectomy is also performed in some women prior to treatment with chemoradiation to provide information regarding radiation fields. Sentinel lymph node biopsy is currently investigational. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Surgical evaluation of lymph nodes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/1\">",
"      Benedet JL, Bender H, Jones H 3rd, et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000; 70:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/2\">",
"      Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009; 105:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/3\">",
"      Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet 2009; 105:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/4\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     Cervix Uteri. In: American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.395.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/6\">",
"      Lagasse LD, Creasman WT, Shingleton HM, et al. Results and complications of operative staging in cervical cancer: experience of the Gynecologic Oncology Group. Gynecol Oncol 1980; 9:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/7\">",
"      LaPolla JP, Schlaerth JB, Gaddis O, Morrow CP. The influence of surgical staging on the evaluation and treatment of patients with cervical carcinoma. Gynecol Oncol 1986; 24:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/8\">",
"      Hricak H, Gatsonis C, Chi DS, et al. Role of imaging in pretreatment evaluation of early invasive cervical cancer: results of the intergroup study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183. J Clin Oncol 2005; 23:9329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/9\">",
"      Quinn MA, Benedet JL, Odicino F, et al. Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95 Suppl 1:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/10\">",
"      Amendola MA, Hricak H, Mitchell DG, et al. Utilization of diagnostic studies in the pretreatment evaluation of invasive cervical cancer in the United States: results of intergroup protocol ACRIN 6651/GOG 183. J Clin Oncol 2005; 23:7454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/11\">",
"      Grigsby PW, Siegel BA, Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol 2001; 19:3745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/12\">",
"      Scheidler J, Hricak H, Yu KK, et al. Radiological evaluation of lymph node metastases in patients with cervical cancer. A meta-analysis. JAMA 1997; 278:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/13\">",
"      Greer BE, Koh WJ, Abu-Rustum NR, et al. Cervical cancer. J Natl Compr Canc Netw 2010; 8:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/14\">",
"      Mitchell DG, Snyder B, Coakley F, et al. Early invasive cervical cancer: tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/GOG 183 Intergroup Study. J Clin Oncol 2006; 24:5687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/15\">",
"      Bhosale P, Peungjesada S, Devine C, et al. Role of magnetic resonance imaging as an adjunct to clinical staging in cervical carcinoma. J Comput Assist Tomogr 2010; 34:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/16\">",
"      Ozsarlak O, Tjalma W, Schepens E, et al. The correlation of preoperative CT, MR imaging, and clinical staging (FIGO) with histopathology findings in primary cervical carcinoma. Eur Radiol 2003; 13:2338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/17\">",
"      Hancke K, Heilmann V, Straka P, et al. Pretreatment staging of cervical cancer: is imaging better than palpation?: Role of CT and MRI in preoperative staging of cervical cancer: single institution results for 255 patients. Ann Surg Oncol 2008; 15:2856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/18\">",
"      Balleyguier C, Sala E, Da Cunha T, et al. Staging of uterine cervical cancer with MRI: guidelines of the European Society of Urogenital Radiology. Eur Radiol 2011; 21:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/19\">",
"      Bipat S, Glas AS, van der Velden J, et al. Computed tomography and magnetic resonance imaging in staging of uterine cervical carcinoma: a systematic review. Gynecol Oncol 2003; 91:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/20\">",
"      Showalter TN, Miller TR, Huettner P, et al. 18F-fluorodeoxyglucose-positron emission tomography and pathologic tumor size in early-stage invasive cervical cancer. Int J Gynecol Cancer 2009; 19:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/21\">",
"      Singh N, Arif S. Histopathologic parameters of prognosis in cervical cancer--a review. Int J Gynecol Cancer 2004; 14:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/22\">",
"      Follen M, Levenback CF, Iyer RB, et al. Imaging in cervical cancer. Cancer 2003; 98:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/23\">",
"      Kumar R, Chauhan A, Jana S, Dadparvar S. Positron emission tomography in gynecological malignancies. Expert Rev Anticancer Ther 2006; 6:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/24\">",
"      Rajendran JG, Greer BE. Expanding role of positron emission tomography in cancer of the uterine cervix. J Natl Compr Canc Netw 2006; 4:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/25\">",
"      Wolfson AH. Magnetic resonance imaging and positron-emission tomography imaging in the 21st century as tools for the evaluation and management of patients with invasive cervical carcinoma. Semin Radiat Oncol 2006; 16:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/26\">",
"      Sironi S, Buda A, Picchio M, et al. Lymph node metastasis in patients with clinical early-stage cervical cancer: detection with integrated FDG PET/CT. Radiology 2006; 238:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/27\">",
"      Selman TJ, Mann C, Zamora J, et al. Diagnostic accuracy of tests for lymph node status in primary cervical cancer: a systematic review and meta-analysis. CMAJ 2008; 178:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/28\">",
"      Choi HJ, Roh JW, Seo SS, et al. Comparison of the accuracy of magnetic resonance imaging and positron emission tomography/computed tomography in the presurgical detection of lymph node metastases in patients with uterine cervical carcinoma: a prospective study. Cancer 2006; 106:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/29\">",
"      Loft A, Berthelsen AK, Roed H, et al. The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study. Gynecol Oncol 2007; 106:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/30\">",
"      Boughanim M, Leboulleux S, Rey A, et al. Histologic results of para-aortic lymphadenectomy in patients treated for stage IB2/II cervical cancer with negative [18F]fluorodeoxyglucose positron emission tomography scans in the para-aortic area. J Clin Oncol 2008; 26:2558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/31\">",
"      Havrilesky LJ, Kulasingam SL, Matchar DB, Myers ER. FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol 2005; 97:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/32\">",
"      Ramirez PT, Jhingran A, Macapinlac HA, et al. Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer: a prospective correlation of surgical findings with positron emission tomography/computed tomography findings. Cancer 2011; 117:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/33\">",
"      Leblanc E, Gauthier H, Querleu D, et al. Accuracy of 18-fluoro-2-deoxy-D-glucose positron emission tomography in the pretherapeutic detection of occult para-aortic node involvement in patients with a locally advanced cervical carcinoma. Ann Surg Oncol 2011; 18:2302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/34\">",
"      Uzan C, Souadka A, Gouy S, et al. Analysis of morbidity and clinical implications of laparoscopic para-aortic lymphadenectomy in a continuous series of 98 patients with advanced-stage cervical cancer and negative PET-CT imaging in the para-aortic area. Oncologist 2011; 16:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/35\">",
"      Cosin JA, Fowler JM, Chen MD, et al. Pretreatment surgical staging of patients with cervical carcinoma: the case for lymph node debulking. Cancer 1998; 82:2241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/36\">",
"      Goff BA, Muntz HG, Paley PJ, et al. Impact of surgical staging in women with locally advanced cervical cancer. Gynecol Oncol 1999; 74:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/37\">",
"      Cormier B, Diaz JP, Shih K, et al. Establishing a sentinel lymph node mapping algorithm for the treatment of early cervical cancer. Gynecol Oncol 2011; 122:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/38\">",
"      Robison K, Holman LL, Moore RG. Update on sentinel lymph node evaluation in gynecologic malignancies. Curr Opin Obstet Gynecol 2011; 23:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/39\">",
"      Gold MA, Tian C, Whitney CW, et al. Surgical versus radiographic determination of para-aortic lymph node metastases before chemoradiation for locally advanced cervical carcinoma: a Gynecologic Oncology Group Study. Cancer 2008; 112:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/40\">",
"      Sevin BU, Nadji M, Averette HE, et al. Microinvasive carcinoma of the cervix. Cancer 1992; 70:2121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/41\">",
"      Reynolds EA, Tierney K, Keeney GL, et al. Analysis of outcomes of microinvasive adenocarcinoma of the uterine cervix by treatment type. Obstet Gynecol 2010; 116:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/42\">",
"      Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. Diagnosis and treatment of cervical carcinomas, number 35, May 2002. Obstet Gynecol 2002; 99:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/43\">",
"      Benedet JL, Anderson GH. Stage IA carcinoma of the cervix revisited. Obstet Gynecol 1996; 87:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/44\">",
"      Todo Y, Yamamoto R, Minobe S, et al. Risk factors for postoperative lower-extremity lymphedema in endometrial cancer survivors who had treatment including lymphadenectomy. Gynecol Oncol 2010; 119:60.",
"     </a>",
"    </li>",
"    <li>",
"     https://gogmember.gog.org/manuals/pdf/surgman.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/46\">",
"      Dowdy SC, Aletti G, Cliby WA, et al. Extra-peritoneal laparoscopic para-aortic lymphadenectomy--a prospective cohort study of 293 patients with endometrial cancer. Gynecol Oncol 2008; 111:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/47\">",
"      Zanvettor PH, Filho DF, Neves AR, et al. Laparoscopic surgical staging of locally advanced cervix cancer (IB2 to IVA): initial experience. Gynecol Oncol 2011; 120:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/48\">",
"      Moore KN, Gold MA, McMeekin DS, et al. Extraperitoneal para-aortic lymph node evaluation for cervical cancer via pfannenstiel incision: technique and peri-operative outcomes. Gynecol Oncol 2008; 108:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/49\">",
"      Sonoda Y, Leblanc E, Querleu D, et al. Prospective evaluation of surgical staging of advanced cervical cancer via a laparoscopic extraperitoneal approach. Gynecol Oncol 2003; 91:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/50\">",
"      Marnitz S, K&ouml;hler C, Roth C, et al. Is there a benefit of pretreatment laparoscopic transperitoneal surgical staging in patients with advanced cervical cancer? Gynecol Oncol 2005; 99:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/51\">",
"      Cibula D, Abu-Rustum NR, Dusek L, et al. Bilateral ultrastaging of sentinel lymph node in cervical cancer: Lowering the false-negative rate and improving the detection of micrometastasis. Gynecol Oncol 2012; 127:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/52\">",
"      Hauspy J, Beiner M, Harley I, et al. Sentinel lymph nodes in early stage cervical cancer. Gynecol Oncol 2007; 105:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/53\">",
"      Frumovitz M, Ramirez PT, Levenback CF. Lymphatic mapping and sentinel lymph node detection in women with cervical cancer. Gynecol Oncol 2008; 110:S17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/54\">",
"      Esajas MD, Duk JM, de Bruijn HW, et al. Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer. J Clin Oncol 2001; 19:3960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/55\">",
"      Chan YM, Ng TY, Ngan HY, Wong LC. Monitoring of serum squamous cell carcinoma antigen levels in invasive cervical cancer: is it cost-effective? Gynecol Oncol 2002; 84:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/56\">",
"      Gaarenstroom KN, Kenter GG, Bonfrer JM, et al. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis? Gynecol Oncol 2000; 77:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/57\">",
"      Massuger LF, Koper NP, Thomas CM, et al. Improvement of clinical staging in cervical cancer with serum squamous cell carcinoma antigen and CA 125 determinations. Gynecol Oncol 1997; 64:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/58\">",
"      Lin H, ChangChien CC, Huang EY, et al. The role of pretreatment squamous cell carcinoma antigen in predicting nodal metastasis in early stage cervical cancer. Acta Obstet Gynecol Scand 2000; 79:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/59\">",
"      Duk JM, Groenier KH, de Bruijn HW, et al. Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma. J Clin Oncol 1996; 14:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/60\">",
"      Bolli JA, Doering DL, Bosscher JR, et al. Squamous cell carcinoma antigen: clinical utility in squamous cell carcinoma of the uterine cervix. Gynecol Oncol 1994; 55:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/61\">",
"      Duk JM, de Bruijn HW, Groenier KH, et al. Cancer of the uterine cervix: sensitivity and specificity of serum squamous cell carcinoma antigen determinations. Gynecol Oncol 1990; 39:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/62\">",
"      Gocze PM, Vahrson HW, Freeman DA. Serum levels of squamous cell carcinoma antigen and ovarian carcinoma antigen (CA 125) in patients with benign and malignant diseases of the uterine cervix. Oncology 1994; 51:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/63\">",
"      Tom&aacute;s C, Risteli J, Risteli L, et al. Use of various epithelial tumor markers and a stromal marker in the assessment of cervical carcinoma. Obstet Gynecol 1991; 77:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/64\">",
"      Sproston AR, Roberts SA, Davidson SE, et al. Serum tumour markers in carcinoma of the uterine cervix and outcome following radiotherapy. Br J Cancer 1995; 72:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/65\">",
"      Bolger BS, Dabbas M, Lopes A, Monaghan JM. Prognostic value of preoperative squamous cell carcinoma antigen level in patients surgically treated for cervical carcinoma. Gynecol Oncol 1997; 65:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/66\">",
"      Callet N, Cohen-Solal Le Nir CC, Berthelot E, Pichon MF. Cancer of the uterine cervix: sensitivity and specificity of serum Cyfra 21.1 determinations. Eur J Gynaecol Oncol 1998; 19:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/67\">",
"      Gaarenstroom KN, Bonfrer JM, Kenter GG, et al. Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer. Cancer 1995; 76:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/68\">",
"      Scambia G, Benedetti Panici P, Foti E, et al. Squamous cell carcinoma antigen: prognostic significance and role in the monitoring of neoadjuvant chemotherapy response in cervical cancer. J Clin Oncol 1994; 12:2309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/69\">",
"      Juang CM, Wang PH, Yen MS, et al. Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix. Gynecol Oncol 2000; 76:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21849/abstract/70\">",
"      Reesink-Peters N, van der Velden J, Ten Hoor KA, et al. Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer. J Clin Oncol 2005; 23:1455.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3244 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-F0948400E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_21_21849=[""].join("\n");
var outline_f21_21_21849=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STAGING SYSTEMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      FIGO system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TNM system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      STAGING PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      FURTHER EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10161218\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10308919\">",
"      - Clinical approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Tumor size and local spread",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Lymph node metastases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10161497\">",
"      - Upper urinary tract involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Surgical evaluation of lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4844274\">",
"      - Lymph node dissection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4844282\">",
"      - Sentinel lymph node biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3481633\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3481640\">",
"      - Routine evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3481647\">",
"      - Tumor markers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3244\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3244|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/50/27425\" title=\"figure 1\">",
"      Lymph nodes female",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/44/38596\" title=\"figure 2\">",
"      Female pelvic lymphadenectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3244|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/28/28108\" title=\"table 1\">",
"      Cervical cancer survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/6/33902\" title=\"table 2\">",
"      Staging cervical cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30762?source=related_link\">",
"      Cervical intraepithelial neoplasia: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=related_link\">",
"      Diagnosis of urinary tract obstruction and hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=related_link\">",
"      Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4455?source=related_link\">",
"      Laparoscopic pelvic and paraaortic lymphadenectomy in gynecologic cancers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=related_link\">",
"      Management of early stage cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=related_link\">",
"      Management of locally advanced cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/32/28163?source=related_link\">",
"      Patient information: Cervical cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/4/15429?source=related_link\">",
"      Patient information: Cervical cancer treatment; early stage cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30436?source=related_link\">",
"      Patient information: Fertility preservation in women with early stage cervical cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=related_link\">",
"      Preoperative medical evaluation of the healthy patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14730?source=related_link\">",
"      Radical hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=related_link\">",
"      Screening for cervical cancer: Rationale and recommendations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_21_21850="Drug-induced neutropenia and agranulocytosis";
var content_f21_21_21850=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Drug-induced neutropenia and agranulocytosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/21/21850/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/21/21850/contributors\">",
"     Thomas D Coates, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/21/21850/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/21/21850/contributors\">",
"     Laurence A Boxer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/21/21850/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/21/21850/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/21/21850/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of neutropenia in adults are acquired and are due to decreased granulocyte production or increased destruction. Neutropenia can be predictable and dose related, as in the case of cytotoxic chemotherapy, or an idiosyncratic reaction. The mechanisms of the neutropenia are varied and the propensity to infection depends upon the adequacy of bone marrow reserve. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=see_link\">",
"     \"Overview of neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drug-induced neutropenia and agranulocytosis will be reviewed here. Others causes of acquired neutropenia, such as primary immune mechanisms, chemotherapy, and infections, as well as congenital neutropenia in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42520?source=see_link\">",
"     \"Immune neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10473?source=see_link\">",
"     \"Infectious causes of neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=see_link\">",
"     \"Congenital neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link\">",
"     \"Overview of neutropenic fever syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The overall approach to the patient with neutropenia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=see_link\">",
"     \"Overview of neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutropenia is defined as an absolute neutrophil count (ANC)",
"    <span class=\"nowrap\">",
"     &lt;1500/microL.",
"    </span>",
"    The ANC is numerically equal to the product of the white blood cell count (WBC) and the fraction of polymorphonuclear cells (PMNs) and band forms noted on the differential analysis:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;ANC = WBC",
"    <span class=\"nowrap\">",
"     (cells/microL)",
"    </span>",
"    x percent (PMNs &nbsp;+ &nbsp;bands) &divide; 100",
"   </p>",
"   <p>",
"    As an example, a patient with a total WBC of",
"    <span class=\"nowrap\">",
"     3500/microL,",
"    </span>",
"    30 percent PMNs and 1 percent bands would have an ANC = 3500 x (30 + 1) &divide; 100 =",
"    <span class=\"nowrap\">",
"     1085/microL.",
"    </span>",
"   </p>",
"   <p>",
"    Neutrophilic metamyelocytes and younger forms are not included in this calculation (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?12/1/12305?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). The risk of infection increases when the ANC falls to less than",
"    <span class=\"nowrap\">",
"     1000/microL,",
"    </span>",
"    and is most clinically significant when the ANC is",
"    <span class=\"nowrap\">",
"     &lt;500/microL",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef63903 \" href=\"UTD.htm?10/19/10555\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The terms leukopenia and granulocytopenia are generally used interchangeably with neutropenia, although they are somewhat different. Leukopenia refers specifically to a low WBC due to any cause, while granulocytopenia refers to a reduced number of granulocytes.",
"   </p>",
"   <p>",
"    Agranulocytosis literally means the absence of granulocytes (ie, ANC of zero), although the term is often used loosely to indicate severe degrees of neutropenia (ie, ANC &lt;100, &lt;200 or even",
"    <span class=\"nowrap\">",
"     &lt;500/microL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     AGRANULOCYTOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agranulocytosis is a rare condition with a reported incidence ranging from 1 to 5 cases per million population per year [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/2-8\">",
"     2-8",
"    </a>",
"    ]. An association with drug use can be found in about 70 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific risk factors for agranulocytosis were evaluated in a prospective survey performed by the International Aplastic Anemia and Agranulocytosis Study (IAAAS) in Europe and Israel from 1980 to 1986 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence rose sharply with age; only 10 percent of cases occurred in children and young adults, while more than 50 percent of cases occurred in patients over age fifty.",
"     </li>",
"     <li>",
"      Agranulocytosis was almost twice as frequent in women, accounting for approximately 70 percent of cases. The gender difference may be due in part to greater consumption of higher risk drugs by adult females. This hypothesis is supported by the lack of preponderance of agranulocytosis in female children [",
"      <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/11\">",
"       11",
"      </a>",
"      ]. There may, however, be a true increase in incidence in women. In a study of 11,555 patients receiving the atypical antipsychotic agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      , the risk of agranulocytosis was significantly higher among women [",
"      <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other risk factors for agranulocytosis include [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A possible increase in risk in patients with infectious mononucleosis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Impaired drug excretion in the urine due to renal failure or the concomitant use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/18/37157?source=see_link\">",
"       probenecid",
"      </a>",
"      in patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"       captopril",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Underlying autoimmune disease.",
"     </li>",
"     <li>",
"      Combination therapy with an angiotensin converting enzyme inhibitor and interferon may be associated with a particularly high risk of severe neutropenia. In a series of patients with mixed cryoglobulinemia who were treated with interferon, severe neutropenia developed within a few days in all three patients also receiving an ACE inhibitor but in none of 35 patients treated with interferon alone [",
"      <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is evidence for genetic susceptibility in certain populations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The HLA-B38 phenotype and the combined alleles DR4 and DQw3, which occur frequently in Ashkenazi Jews, occur with increased frequency in patients with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      -induced agranulocytosis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/17\">",
"       17",
"      </a>",
"      ]. The associated gene within the MHC region appears to be marked by variants of the heat shock protein 70 gene [",
"      <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among Japanese patients with Graves' disease, the HLA DRB1*08032 allele appears to be strongly associated with susceptibility to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"       methimazole",
"      </a>",
"      -induced agranulocytosis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Agranulocytosis secondary to treatment with levamisole, an agent no longer available in North America for human use, has been associated with presence of HLA-B27 [",
"      <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/20\">",
"       20",
"      </a>",
"      ]. This agent has reappeared as a cause of agranulocytosis or severe neutropenia as a result of its being added to cocaine and heroin, perhaps to potentiate its euphoric effects [",
"      <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/21-23\">",
"       21-23",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Cocaine and heroin'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H694262921\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of adverse prognostic factors have been reported for patients with agranulocytosis. These include [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/1,24\">",
"     1,24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &gt;65 years",
"     </li>",
"     <li>",
"      Absolute neutrophil count at the time of diagnosis",
"      <span class=\"nowrap\">",
"       &lt;100/microL",
"      </span>",
"     </li>",
"     <li>",
"      Development of severe intercurrent infection (eg, septicemia, septic shock)",
"     </li>",
"     <li>",
"      Pre-existing comorbidities (eg, renal, cardiac, respiratory, systemic inflammatory diseases)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DRUG-INDUCED NEUTROPENIA/AGRANULOCYTOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Implicated agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of drugs have been implicated as potential causes of severe neutropenia or agranulocytosis. Evidence for such a relationship is based upon an accumulation of case reports, spontaneous reports to registries, cohort studies, and population and case control studies. Drugs can be classified as definite, probable, or possible causes of neutropenia based upon the available evidence.",
"   </p>",
"   <p>",
"    There are a number of drugs that are considered to have a high risk for agranulocytosis based upon definite and unequivocal evidence (",
"    <a class=\"graphic graphic_table graphicRef65507 \" href=\"UTD.htm?39/4/40013\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/12,16,17,25\">",
"     12,16,17,25",
"    </a>",
"    ]. This list excludes drugs that produce agranulocytosis on the basis of bone marrow suppression (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Among the drugs that are more commonly associated with agranulocytosis are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    , the thionamides (antithyroid drugs),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    . Other drugs with multiple reports of agranulocytosis include other antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/26\">",
"     26",
"    </a>",
"    ], ACE inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/16,27,28\">",
"     16,27,28",
"    </a>",
"    ], H2 blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/29-31\">",
"     29-31",
"    </a>",
"    ], nonsteroidal antiinflammatory drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/32-38\">",
"     32-38",
"    </a>",
"    ], amodiaquine [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/39,40\">",
"     39,40",
"    </a>",
"    ], antiarrhythmic drugs such as tocainide,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/41-44\">",
"     41-44",
"    </a>",
"    ], aminoglutethimide [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/45,46\">",
"     45,46",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/47\">",
"     47",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"     deferiprone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a systematic literature review of English- and German-language reports of patients with non-chemotherapy drug-induced agranulocytosis, the following 11 drugs accounted for more than 50 percent of definite or probable reports: carbimazole,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    , dipyrone,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/9/5271?source=see_link\">",
"     propylthiouracil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/1\">",
"     1",
"    </a>",
"    ]. A listing of all case reports of agranulocytosis included in this 2007 systematic review is available at:",
"    <a class=\"external\" href=\"file://www.adverse-effects.com/agranulocytosis/case_reports.html\">",
"     www.adverse-effects.com/agranulocytosis/case_reports.html",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative and absolute risks of drug-induced agranulocytosis were evaluated in a study of all patients hospitalized in the Netherlands for a diagnosis of agranulocytosis (defined as an ANC",
"    <span class=\"nowrap\">",
"     &lt;500/microL)",
"    </span>",
"    during the years 1987 through 1990. The following results were found [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The highest relative risks for development of agranulocytosis were found for antithyroid drugs,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      , dipyrone combined with analgesics,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/20/43336?source=see_link\">",
"       clomipramine",
"      </a>",
"      , and carbimazole.",
"     </li>",
"     <li>",
"      Three drugs (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"       methimazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      ) were responsible for 42 percent of all cases, with excess risks (cases of agranulocytosis per million users following 10 days of exposure) of 10.1, 3.6, and 1.2, respectively.",
"     </li>",
"     <li>",
"      Calcium dobesilate (Doxium), a veno-tonic drug widely prescribed in Europe, Latin America, Asia, and the Middle East, has been associated with a high incidence of agranulocytosis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Psychotropic drugs and anticonvulsants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many psychotropic agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    , the phenothiazines and the tri- and tetra-cyclic antidepressants, have been associated with neutropenia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    agranulocytosis. Similarly, many of the commonly used anticonvulsants can cause hypersensitivity reactions (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ) and are associated with neutropenia. Clinicians need to be aware of this possibility and either monitor blood counts in patients taking such agents on a regular basis or alert the patient to the possibility that fever",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infection may be signs of this toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link&amp;anchor=H3#H3\">",
"     \"Pharmacology of antiepileptic drugs\", section on 'Carbamazepine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Clozapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     Clozapine",
"    </a>",
"    , an atypical antipsychotic agent, is used only for schizophrenia unresponsive to other therapies due to the risk of agranulocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/12,17,52\">",
"     12,17,52",
"    </a>",
"    ]. The cumulative risk of agranulocytosis is approximately 0.8 to 1.5 percent at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/12,52\">",
"     12,52",
"    </a>",
"    ], with little further increase over time [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/12\">",
"     12",
"    </a>",
"    ]. The majority of cases (84 percent) occur within the first three months of therapy, which constitutes the rationale for monitoring the white blood cell count, especially soon after therapy has been instituted. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Prevention and screening'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link&amp;anchor=H76524735#H76524735\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\", section on 'Clozapine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Olanzapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     Olanzapine",
"    </a>",
"    , related structurally to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    , has been recommended as an antipsychotic agent for patients with clozapine-induced granulocytopenia or agranulocytosis. However, the safety of this approach is uncertain due in part to the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Metabolites of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      were toxic in vitro to neutrophils from two patients with a history of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      -induced agranulocytosis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One patient developed agranulocytosis following treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      ; he had been treated previously with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      without hematologic complications [",
"      <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another patient with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      -induced neutropenia developed reversible neutropenia after being switched to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1033710\">",
"    <span class=\"h2\">",
"     Deferiprone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"     Deferiprone",
"    </a>",
"    is an oral iron-chelating agent that has been in use in humans since the 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/48\">",
"     48",
"    </a>",
"    ]. It has been available in many European countries for a number of years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/48,49\">",
"     48,49",
"    </a>",
"    ] and was approved for use in the United States in 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/56\">",
"     56",
"    </a>",
"    ]. Agranulocytosis has been reported in 0.5 to 3.6 percent of patients in various studies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/48\">",
"     48",
"    </a>",
"    ]. An ANC of less than 0.2 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    was seen in",
"    <span class=\"nowrap\">",
"     0.2/100",
"    </span>",
"    patient years and 0.5 to 1500 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    in 2.8 per 100 patient years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/49\">",
"     49",
"    </a>",
"    ]. The onset of agranulocytosis or neutropenia can occur between zero and 19 months or zero and 70 months, respectively, but usually occurs in the first year after starting the drug.",
"   </p>",
"   <p>",
"    Both neutropenia and agranulocytosis are reversible after stopping the drug. While some patients with neutropenia have done well after restarting the drug, it is recommended that patients will full agranulocytosis not be rechallenged with this agent. There have been reported deaths from sepsis due to agranulocytosis. At close inspection of these cases, the physicians and patients were not aware of the possibility of this side effect and therefore did not respond properly when fever developed. Because of this risk, it is recommended that monitoring of the ANC be performed in all patients taking the medication, and they be instructed to stop the drug and seek medical attention if there is any development of fever [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/48,56,57\">",
"     48,56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A report of fatal aplasia in a patient with Diamond-Blackfan anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/58\">",
"     58",
"    </a>",
"    ] has lead to concern regarding the use of this agent in patients with marrow failure syndromes. The mechanism of the agranulocytosis is unclear, though it is likely different from that of milder neutropenia. Bone marrow examination has shown early myeloid arrest at the progranulocyte stage [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/59\">",
"     59",
"    </a>",
"    ], as well as more global aplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Thionamides",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of agranulocytosis with thionamide therapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    [MMI],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/9/5271?source=see_link\">",
"     propylthiouracil",
"    </a>",
"    [PTU], or carbimazole, a drug available in Europe that is completely metabolized to MMI) ranges from 0.2 to 0.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/19,60-65\">",
"     19,60-65",
"    </a>",
"    ]. In one study, agranulocytosis was more frequent in elderly patients taking MMI in doses &gt;40",
"    <span class=\"nowrap\">",
"     mg/day;",
"    </span>",
"    in comparison, the prevalence with PTU was dose-independent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/64\">",
"     64",
"    </a>",
"    ]. In another report, most cases occurred within three months after treatment was begun [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/62\">",
"     62",
"    </a>",
"    ]. However, these findings are not uniform as a Japanese study found that the development of thionamide-induced agranulocytosis was independent of dose, age, duration of treatment, or second exposure to the thionamide [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/65\">",
"     65",
"    </a>",
"    ]. Controversy exists as to the value of monitoring white blood cell counts in patients taking these medications. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Prevention and screening'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Sulfasalazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     Sulfasalazine",
"    </a>",
"    , an agent that is reduced by the bacterial enzyme azoreductase to sulfapyridine and 5-aminosalicylic acid, is used in the treatment of inflammatory bowel disease and rheumatoid arthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=see_link\">",
"     \"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/27/2490?source=see_link\">",
"     \"Sulfasalazine in the treatment of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most episodes of neutropenia, which occur in 1 to 2 percent of patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , are mild and transient, although life-threatening agranulocytosis can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/66-69\">",
"     66-69",
"    </a>",
"    ]. The estimated frequency of agranulocytosis is 0.6 percent in patients with arthritis and 0.06 percent in those with inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/67\">",
"     67",
"    </a>",
"    ]. In this review, there were no cases of agranulocytosis following the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    , a related 5-aminosalicylic acid derivative. Serious episodes of agranulocytosis are usually observed within the first three months of therapy and often within the first six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The adverse effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    on white cells may be either idiosyncratic or dose-dependent. Distinguishing the different mechanisms is clinically important. Agranulocytosis caused by a hypersensitivity reaction requires drug discontinuation without rechallenge; by comparison, some investigators feel that benign neutropenia can be treated with dose reduction.",
"   </p>",
"   <p>",
"    Other sulfa drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , also are common causes of agranulocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/25,70,71\">",
"     25,70,71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Ticlopidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     Ticlopidine",
"    </a>",
"    is a thienopyridine antiplatelet drug that is effective in stroke patients and in preventing coronary stent thrombosis after coronary stenting. However, it causes neutropenia at a rate of approximately 2.4 percent, usually within the first three months of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. Fatal agranulocytosis with thrombocytopenia has been seen as early as three to four weeks after starting ticlopidine [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. Data from the Food and Drug Administration's MedWatch program collected between 1992 and 1997 revealed 116 cases of agranulocytosis associated with ticlopidine, with 22 deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe hematologic reactions to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    , in addition to neutropenia and thrombocytopenia, include thrombotic thrombocytopenic purpura-hemolytic uremic syndrome and aplastic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link&amp;anchor=H112796005#H112796005\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Antiplatelet agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the above risks, which are not seen or seen much less often with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , clopidogrel has become the thienopyridine of choice. When",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    is used, it is essential to obtain a complete blood count with platelet count and white cell differential every two weeks for four months after the initiation of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7617817\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutropenia has been observed following use of the chimeric anti-CD20 monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    for both malignant (eg, lymphoproliferative) and non-malignant (eg, rheumatic) disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. It may be severe (grades III-IV), is associated with the period of B cell depletion, with fever and infection in about 17 percent of the cases, and occurs a median of 38 to 175 days following the last rituximab dose, with a median duration of 5 to 77 days [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/79,81\">",
"     79,81",
"    </a>",
"    ]. Retreatment with rituximab may result in recurrent episodes. The mechanism behind &ldquo;late onset neutropenia&rdquo; (LON) is unknown, although direct toxicity is thought to be unlikely [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. Myeloid maturation arrest has been noted in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Polymorphisms in FCGR3A (FcgammaRIIIa), a low-affinity receptor capable of binding to the Fc portion of complexed but not monomeric IgG, have been implicated in this process [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. This issue was evaluated in a retrospective analysis of 115 patients with diffuse large B cell lymphoma treated with CHOP plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    chemotherapy, following which 6 percent developed LON [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/86\">",
"     86",
"    </a>",
"    ]. LON developed in 50, 7, and 2 percent of those with the VV, VF, and FF FCGR3A polymorphisms, respectively.",
"   </p>",
"   <p>",
"    Of interest, in a review of 92 patients who developed LON, all except one had achieved a complete remission from their underlying lymphoproliferative disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/87\">",
"     87",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    was discontinued from further chemotherapy regimens in many of these patients with no negative impact on their final outcome.",
"   </p>",
"   <p>",
"    The role of growth factors once LON appears is ill-defined and the decision to use them should be made on a case-by-case basis. In the series of 11 patients with rheumatologic disease who developed LON following treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , the median duration of neutropenia was nine days (range: 4 to 20 days), with nadir absolute neutrophil counts ranging from 100 to",
"    <span class=\"nowrap\">",
"     1200/microL",
"    </span>",
"    (median",
"    <span class=\"nowrap\">",
"     700/microL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/79\">",
"     79",
"    </a>",
"    ]. Seven of the 11 patients were hospitalized, six with sepsis and one with febrile neutropenia; all required treatment with intravenous antibiotics and six of the seven received treatment with G-CSF. While the neutrophil count recovered in all cases, sustained neutropenia lasting 19 to 20 days was observed in three of the patients who did not receive treatment with G-CSF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cocaine and heroin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of heroin and cocaine has been associated with agranulocytosis, likely because these illicit agents were adulterated with levamisole [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/20-22,88\">",
"     20-22,88",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two basic mechanisms by which drugs cause neutropenia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    agranulocytosis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immune mediated destruction of circulating neutrophils by drug-dependent or drug-induced antibodies",
"     </li>",
"     <li>",
"      Direct toxic effects upon marrow granulocytic precursors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both mechanisms appear to be mediated by reactive metabolites [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/89\">",
"     89",
"    </a>",
"    ]. The enzyme system most likely responsible for the formation of reactive metabolites is the NADPH",
"    <span class=\"nowrap\">",
"     oxidase/myeloperoxidase",
"    </span>",
"    system found in neutrophils and monocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/90-92\">",
"     90-92",
"    </a>",
"    ]. Drugs that are known to be oxidized to reactive metabolites by this system, and which have been associated with agranulocytosis, include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    , sulfonamides,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    , and amodiaquine [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/91,93\">",
"     91,93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Immune-mediated destruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The current hypothesis of immune-mediated drug-induced agranulocytosis suggests that the drug, or more commonly a reactive metabolite of the drug, irreversibly binds to the neutrophil membrane. In some cases, the reactive metabolite results in the production of antibodies or T cells directed against the altered membrane structure; in others, true antineutrophil autoantibodies are produced that do not require the presence of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examples of drugs that bind to the neutrophil membrane and act as haptens in the production of autoantibodies are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/9/5271?source=see_link\">",
"     propylthiouracil",
"    </a>",
"    (PTU), the antimalarial drug amodiaquine and one of its major metabolites, mono-desethyl amodiaquine, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/39,40,44,60,92\">",
"     39,40,44,60,92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With PTU, highly reactive oxidative products are generated using activated neutrophil",
"    <span class=\"nowrap\">",
"     myeloperoxidase/",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"      hydrogen peroxide",
"     </a>",
"     /chloride.",
"    </span>",
"    The products, propyl-thioester, sulfinic acid, and sulfonic acid are all thought to be reactive and form macromolecules that bind covalently to the neutrophil membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/92\">",
"     92",
"    </a>",
"    ]. This macromolecular complex can then induce antibodies capable of binding to the haptenized membrane, leading to the phagocytic destruction of the sensitized cell. Cytotoxicity in one patient was demonstrated to be mediated by a complement-dependent IgM antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dipyrone, a pyrazolone analgesic, can also induce the production of antineutrophil antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/95\">",
"     95",
"    </a>",
"    ]. The drug was banned by the United States FDA in 1977 because of a high risk of agranulocytosis, but is still available in some countries [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/25,95,96\">",
"     25,95,96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antineutrophil antibodies can be demonstrated by a variety of techniques in most cases of immune-mediated drug-induced agranulocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/13\">",
"     13",
"    </a>",
"    ]. Laboratory demonstration of antibody binding to target cells often requires the presence of the suspect drug or its metabolites [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/90\">",
"     90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24614?source=see_link&amp;anchor=H6#H6\">",
"     \"Laboratory evaluation of neutropenia and neutrophil dysfunction\", section on 'Tests for the presence of neutrophil antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Direct and indirect toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some drugs can directly damage myeloid precursors. As an example, detoxification of many nonpolar compounds requires conversion to a chemically reactive intermediate that may bind to nuclear material or cytoplasmic proteins, causing direct toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/89\">",
"     89",
"    </a>",
"    ]. This mechanism has been described with phenothiazines, in particular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/43,97\">",
"     43,97",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/98-100\">",
"     98-100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       Clozapine",
"      </a>",
"      is oxidized by granulocytes to a nitrenium ion formed by chlorination of the nitrogen bridge between the two aromatic rings [",
"      <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/98\">",
"       98",
"      </a>",
"      ]. This metabolite binds covalently and irreversibly to, and is toxic to, neutrophils and their bone marrow precursors [",
"      <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/99\">",
"       99",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       Dapsone",
"      </a>",
"      is metabolized to a highly reactive hydroxylamine which is toxic to bone marrow myeloid cells [",
"      <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/100\">",
"       100",
"      </a>",
"      ]. In one study over a 17-year period, agranulocytosis was estimated to develop in 1 of 240 to 425 patients receiving dapsone therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific drug-induced reductions in the number and growth of colony forming units can be seen by culture of bone marrow aspirates from affected patients with and without the drug in the medium [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of severe neutropenia or agranulocytosis present within the first six months and usually within the first three months after beginning the offending drug [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/1,12,47,62,66,69,102\">",
"     1,12,47,62,66,69,102",
"    </a>",
"    ]. As an example, a review of the literature concerning vancomycin-induced neutropenia indicated that most cases occurred after a minimum of seven days of treatment, with the majority occurring at least 20 days after initiation of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/103\">",
"     103",
"    </a>",
"    ]. Many patients are asymptomatic at the time that severe neutropenia is detected, particularly if the patient is being monitored for early detection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical presentation is usually oral ulcerations with or without fever. As the onset of agranulocytosis can be abrupt, sepsis can be the presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. Thus, is it critical that all patients taking drugs that can cause agranulocytosis be counseled about this complication and instructed to stop the medication and seek medical attention immediately if such symptoms occur.",
"   </p>",
"   <p>",
"    Propensity to infection in neutropenic patients is related to adequacy of the marrow reserve pool, and, in patients with decreased reserve, to the ANC (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?12/1/12305?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) and the duration of neutropenia. In a systematic review of patients with severe neutropenia induced by nonchemotherapy drugs, fatal complications were more frequent in patients with absolute neutrophil counts of &lt;100 compared with 100 to 500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    (10 versus 3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=see_link\">",
"     \"Overview of neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical presentation depends in part upon the etiology and pathogenesis of drug-induced neutropenia or agranulocytosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=see_link\">",
"     \"Overview of neutropenia\"",
"    </a>",
"    .) The duration of the process before onset of symptoms may depend in part on the mechanism of the neutropenia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immune-mediated destruction may present days to weeks after beginning the drug, often with acute and explosive symptoms. Rechallenge, or inadvertent subsequent administration, is associated with a prompt recurrence even with low doses.",
"     </li>",
"     <li>",
"      When direct or indirect toxicity is the operative mechanism, the presentation may be delayed for months. The neutropenia is often asymptomatic or presents with an insidious onset. Rechallenge requires both a latent period and high drug doses before recurrence is observed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis in a patient in whom the predominant abnormality is neutropenia or agranulocytosis includes other causes of acquired neutropenia. The diagnosis may be suspected from the history and is established by bone marrow examination and, when relevant, other tests. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=see_link\">",
"     \"Overview of neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among neutropenic patients who present with infection, it may not be clear whether the infection is due to, or the cause of, the neutropenia. This may be a very important distinction to make, particularly if the medication is critical to the patient&rsquo;s care. As certain viral infections can be associated with neutropenia, it would be problematic to permanently discontinue use of an important drug on the mistaken assumption that it is the cause of the neutropenia. Bone marrow examination can be particularly helpful in this case. If the marrow cellularity is normal with a late myeloid arrest, the danger from neutropenia is likely much less, and re-challenge or even continuation with careful monitoring may be possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10473?source=see_link\">",
"     \"Infectious causes of neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PREVENTION AND SCREENING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no effective way to detect the rare patient at high risk for drug-induced severe neutropenia or agranulocytosis. Monitoring of the white blood cell count and white cell differential in order to permit early detection has been used for several drug regimens, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    and thionamides [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/12,62\">",
"     12,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the benefit of monitoring is uncertain. Routine use remains controversial due to the low incidence of agranulocytosis and the expense of repeated white blood cell and differential counts.",
"   </p>",
"   <p>",
"    In favor of such programs are several studies indicating detection of a large number of patients prior to the development of symptomatic infection, thereby reducing morbidity and mortality. Also in favor of screening is the rapid resolution of neutropenia, often within one to two weeks, once the drug has been discontinued (see",
"    <a class=\"local\" href=\"#H26\">",
"     'Treatment'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Prophylactic monitoring of the white blood cell count and differential has been evaluated primarily with drugs associated with the highest risk of agranulocytosis, namely",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    and thionamides.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Clozapine screening programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of prospectively monitoring the white blood cell count during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    therapy has been evaluated in two large series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      became available in the United States, weekly monitoring of the white blood cell count and differential was required for continued therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/12\">",
"       12",
"      </a>",
"      ]. At 1.5 years, the cumulative incidence of agranulocytosis was 0.9 percent. Two of the 73 patients who developed this complication died of infectious causes.",
"     </li>",
"     <li>",
"      In 4061 Australian patients who were prospectively monitored, the overall incidence of agranulocytosis or neutropenia was 2.6 percent, while the incidence of agranulocytosis was 0.9 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/104\">",
"       104",
"      </a>",
"      ]. There were no deaths from complications of neutropenia or agranulocytosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Weekly monitoring of the white blood cell count and differential during the first six months is required in the United States for all patients taking this agent. Details concerning frequency of monitoring and when to interrupt or discontinue this medication are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6793?source=see_link&amp;anchor=H207044#H207044\">",
"     \"Guidelines for prescribing clozapine in schizophrenia\", section on 'White blood count'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1033971\">",
"    <span class=\"h2\">",
"     Deferiprone screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete blood counts at 7 to 10-day intervals are currently recommended for all patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"     deferiprone",
"    </a>",
"    , and the FDA approval requires that all physicians prescribing this medication counsel patients regarding its use and the risks of fever and neutropenia. Most experienced clinicians agree with this at least for the first year of treatment, although the efficacy of such monitoring has been questioned [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Thionamides",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study from Japan evaluated the efficacy of routine monitoring of the white blood cell count in 15,398 patients with Graves' disease receiving thionamide therapy over a 12-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/62\">",
"     62",
"    </a>",
"    ]. An ANC",
"    <span class=\"nowrap\">",
"     &le;500/microL",
"    </span>",
"    occurred in 55 patients (0.4 percent), and was detected in the absence of infection in 43, 14 of whom became symptomatic several days after withdrawal of the drug despite antimicrobial therapy.",
"   </p>",
"   <p>",
"    Most clinicians in the United States do not recommend periodic monitoring of the white blood cell count during thionamide therapy. Instead, we advise patients taking a thionamide to have a white blood cell count with differential at the earliest sign of a sore throat or other infection, and to discontinue the drug until the result is available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41303?source=see_link\">",
"     \"Pharmacology and toxicity of thionamides\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Withdrawal of the offending agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once severe neutropenia or agranulocytosis is documented in association with a putative offending drug, the drug should be withdrawn regardless of whether the patient is symptomatic. However, some patients will be taking multiple drugs and identifying the possible offending agent may be difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/1,105\">",
"     1,105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neutropenia usually resolves within one to three weeks after cessation of the offending drug, but there is substantial interpatient variability [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/102,105,106\">",
"     102,105,106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 63 episodes in 61 patients, for example, the mean time to recovery was 12 days with a range of 3 to 56 days [",
"      <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/105\">",
"       105",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another series of 10 patients with thionamide-induced agranulocytosis, the median recovery time was 15 days with a range of 5 to 31 days [",
"      <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/106\">",
"       106",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Treatment of associated infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow aspiration and biopsy may be helpful, although an isolated agranulocytosis in a patient taking a high-risk drug may, in some cases, be treated without bone marrow examination. If the patient is febrile, cultures of blood, urine, sputum, and other suspected sites of infection should be taken and the patient should be started on broad-spectrum intravenous antibiotics. Older age, sepsis, shock, and renal failure are poor prognostic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Granulocyte colony-stimulating factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of non-randomized studies have reported excellent results with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) in patients with drug-induced agranulocytosis and secondary infection. The results have generally been characterized as shorter recovery times, less antibiotic use, and shorter length of hospitalization compared with historic or concurrent controls [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/13,24,27,108-113\">",
"     13,24,27,108-113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, for example, neutrophil recovery to an ANC",
"      <span class=\"nowrap\">",
"       &gt;1000/microL",
"      </span>",
"      occurred within one to 15 days (median four days) after initiation of G-CSF in doses of 4 to 10",
"      <span class=\"nowrap\">",
"       microg/kg",
"      </span>",
"      per day [",
"      <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/13\">",
"       13",
"      </a>",
"      ]. Seven of the 22 patients had received aggressive antibiotic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      antifungal treatment for seven or more days before initiation of G-CSF. Two deaths occurred from causes unrelated to G-CSF use. Complete recovery occurred in the remaining 20 patients, with clinical improvement coincident with normalization of the ANC.",
"     </li>",
"     <li>",
"      A second study evaluated the effects of G-CSF on recovery at four and 24 hours after injection in 37 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/109\">",
"       109",
"      </a>",
"      ]. In 29 patients (25 with mild neutropenia, ie, ANC 500 to",
"      <span class=\"nowrap\">",
"       1000/microL),",
"      </span>",
"      recovery from granulocytopenia occurred within four hours and remained normal thereafter. In the remaining eight patients, daily G-CSF injections were required for 2 to 11 days. Recovery within four hours suggests that bone marrow suppression was not present, but rather that neutrophils were being released by G-CSF from a storage pool in the marrow.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to these uncontrolled observations, a nonrandomized prospective controlled trial of 24 patients with a thionamide-induced neutrophil count",
"    <span class=\"nowrap\">",
"     &lt;500/microL",
"    </span>",
"    found no difference in the time to neutrophil recovery between those who received G-CSF and those who did not [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/114\">",
"     114",
"    </a>",
"    ]. However, this trial is difficult to interpret, as most patients in the treatment arm received a subtherapeutic dose of G-CSF of 1 to 2",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day.",
"   </p>",
"   <p>",
"    Although their efficacy is not conclusively proven, growth factors have minimal toxicity in this setting. In spite of the lack of evidence of their efficacy in drug-induced neutropenia outside of the oncology setting [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/89\">",
"     89",
"    </a>",
"    ], it seems likely that most patients with agranulocytosis will receive these drugs. G-CSF can be given (at the recommended dose of 5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day) subcutaneously, empirically, to patients with significant drug-induced neutropenia who are ill and suspected of having reduced marrow reserve. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=see_link\">",
"     \"Overview of neutropenia\"",
"    </a>",
"    .) Treatment with G-CSF can be discontinued when the total white blood cell count exceeds",
"    <span class=\"nowrap\">",
"     10,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/21/21850/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Availability of longer-lasting pegylated G-CSF (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/28/12741?source=see_link\">",
"     pegfilgrastim",
"    </a>",
"    ) provides similar benefits as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     filgrastim",
"    </a>",
"    with a simpler, less frequent, dosing regimen. However, such agents may be associated with increased bone pain and significant leukocytosis in patients who have a short duration of neutropenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=see_link\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=see_link&amp;anchor=H523774254#H523774254\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\", section on 'Pegfilgrastim'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/59/25521?source=see_link\">",
"       \"Patient information: Neutropenia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Diagnosis and differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of drug-induced neutropenia or agranulocytosis is suspected in a patient with a sudden",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    unexpected onset of neutropenia in whom a drug is suspected as the cause. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definitions'",
"    </a>",
"    above.) The diagnosis should be suspected if a patient develops fever, mouth sores, or gingival disease inflammation. In particular, the presence of fever and mouth sores may indicate bone marrow suppression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=see_link\">",
"     \"Overview of neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis is confirmed when all of the following are present:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low to absent absolute neutrophil count",
"     </li>",
"     <li>",
"      Absence of anemia and thrombocytopenia",
"     </li>",
"     <li>",
"      A hypocellular bone marrow that shows normal erythropoiesis and megakaryocytopoiesis, but few if any granulocytic precursors.",
"     </li>",
"     <li>",
"      Return of the neutrophil count to normal when the offending agent is stopped, with or without the concomitant use of a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"       granulocyte colony-stimulating factor",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The differential diagnosis for",
"    <span class=\"nowrap\">",
"     neutropenia/agranulocytosis",
"    </span>",
"    unassociated with drugs is extensive and includes both inherited and acquired forms. The most common conditions to be considered in a patient on chronic medications would be concomitant viral infection or possible nutritional deficiency (eg, copper or vitamin B12 deficiency). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=see_link\">",
"     \"Overview of neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Initial studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate initial studies for such patients include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      CBC, white cell differential, and examination of the peripheral smear",
"     </li>",
"     <li>",
"      If the patient is not ill, the most important initial test is to see if the neutropenia recovers with cessation of the drug.",
"     </li>",
"     <li>",
"      Bacterial and viral studies as appropriate, if the patient is febrile",
"     </li>",
"     <li>",
"      Bone marrow aspiration and biopsy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Cessation of offending drug",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment for drug-induced neutropenia or agranulocytosis is immediate cessation of the offending agent. Patients with a secondary infection should be treated with appropriate antibiotics. It is important to determine if the neutropenia could be related to an intercurrent infection or other cause before deciding for that the medication is causing the neutropenia. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Withdrawal of the offending agent'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Colony-stimulating factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although randomized controlled studies are not available, we recommend the use of a colony-stimulating factor (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    , G-CSF) if the patient is ill from infection and bone marrow suppression is suspected (",
"    <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"     Grade 1C",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Granulocyte colony-stimulating factor'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1033656\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate would like to acknowledge Robert L Baehner, MD, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/1\">",
"      Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 2007; 146:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/2\">",
"      Hamerschlak N, Montezuma MP, Bacal N, et al. Retrospective prevalence and incidence of drug-induced agranulocytosis in the city of S&atilde;o Paulo-Brasil. Rev Paul Med 1993; 111:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/3\">",
"      Strom BL, Carson JL, Schinnar R, et al. Descriptive epidemiology of agranulocytosis. Arch Intern Med 1992; 152:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/4\">",
"      Kaufman DW, Kelly JP, Jurgelon JM, et al. Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur J Haematol Suppl 1996; 60:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/5\">",
"      Billekop K, Mosbech J. [Mortality from agranulocytosis in Denmark during the period 1958-1972]. Ugeskr Laeger 1976; 138:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/6\">",
"      B&ouml;ttiger LE, Furhoff AK, Holmberg L. Drug-induced blood dyscrasias. A ten-year material from the Swedish Adverse Drug Reaction Committee. Acta Med Scand 1979; 205:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/7\">",
"      Wiholm BE, Emanuelsson S. Drug-related blood dyscrasias in a Swedish reporting system, 1985-1994. Eur J Haematol Suppl 1996; 60:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/8\">",
"      Kaufman DW, Kelly JP, Issaragrisil S, et al. Relative incidence of agranulocytosis and aplastic anemia. Am J Hematol 2006; 81:65.",
"     </a>",
"    </li>",
"    <li>",
"     Kaufman DW, Kelly JP, Levy M, et al. The Drug Etiology of Agranulocytosis and Aplastic Anemia, Oxford University Press, New York 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/10\">",
"      Kaufman DW, Kelly JP, Levy M, Shapiro S. Drug etiology of agranulocytosis: Update of the International Agranulocytosis and Aplastic Anemia Study. Pharmacoepidem Drug Safety 1993; 2:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/11\">",
"      Kantero I, Mustala OO, Palva IP. Drug-induced agranulocytosis, with special reference to aminophenazone. IV. Children. Acta Med Scand 1972; 192:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/12\">",
"      Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993; 329:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/13\">",
"      Young NS. Agranulocytosis. JAMA 1994; 271:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/14\">",
"      Levy M, Kelly JP, Kaufman DW, Shapiro S. Risk of agranulocytosis and aplastic anemia in relation to history of infectious mononucleosis: a report from the international agranulocytosis and aplastic anemia study. Ann Hematol 1993; 67:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/15\">",
"      Sinhvi SM, Duchin KL, Willard DA, et al. Renal handling of captopril: effect of probenecid. Clin Pharmacol Ther 1982; 32:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/16\">",
"      Casato M, Pucillo LP, Leoni M, et al. Granulocytopenia after combined therapy with interferon and angiotensin-converting enzyme inhibitors: evidence for a synergistic hematologic toxicity. Am J Med 1995; 99:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/17\">",
"      Yunis JJ, Lieberman J, Yunis EJ. Major histocompatibility complex associations with clozapine-induced agranulocytosis. The USA experience. Drug Saf 1992; 7 Suppl 1:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/18\">",
"      Corzo D, Yunis JJ, Salazar M, et al. The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups. Blood 1995; 86:3835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/19\">",
"      Tamai H, Sudo T, Kimura A, et al. Association between the DRB1*08032 histocompatibility antigen and methimazole-induced agranulocytosis in Japanese patients with Graves disease. Ann Intern Med 1996; 124:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/20\">",
"      Hodinka L, G&eacute;her P, Mer&eacute;tey K, et al. Levamisole-induced neutropenia and agranulocytosis: association with HLA B27 leukocyte agglutinating and lymphocytotoxic antibodies. Int Arch Allergy Appl Immunol 1981; 65:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/21\">",
"      Zhu NY, Legatt DF, Turner AR. Agranulocytosis after consumption of cocaine adulterated with levamisole. Ann Intern Med 2009; 150:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/22\">",
"      Centers for Disease Control and Prevention (CDC). Agranulocytosis associated with cocaine use - four States, March 2008-November 2009. MMWR Morb Mortal Wkly Rep 2009; 58:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/23\">",
"      Muirhead TT, Eide MJ. Images in clinical medicine. Toxic effects of levamisole in a cocaine user. N Engl J Med 2011; 364:e52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/24\">",
"      Andr&egrave;s E, Maloisel F, Zimmer J. The role of haematopoietic growth factors granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the management of drug-induced agranulocytosis. Br J Haematol 2010; 150:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/25\">",
"      van der Klauw MM, Goudsmit R, Halie MR, et al. A population-based case-cohort study of drug-associated agranulocytosis. Arch Intern Med 1999; 159:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/26\">",
"      Andr&egrave;s E, Zimmer J, Mecili M, et al. Clinical presentation and management of drug-induced agranulocytosis. Expert Rev Hematol 2011; 4:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/27\">",
"      Chia HM, Kalra L, Lakhani AK, Samaratunga IR. Filgrastim for low-dose, captopril-induced agranulocytosis. Lancet 1993; 342:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/28\">",
"      Elis A, Lishner M, Lang R, Ravid M. Agranulocytosis associated with enalapril. DICP 1991; 25:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/29\">",
"      Aymard JP, Aymard B, Netter P, et al. Haematological adverse effects of histamine H2-receptor antagonists. Med Toxicol Adverse Drug Exp 1988; 3:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/30\">",
"      List AF, Beaird DH, Kummet T. Ranitidine-induced granulocytopenia: recurrence with cimetidine administration. Ann Intern Med 1988; 108:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/31\">",
"      Brenner LO. Agranulocytosis and ranitidine. Ann Intern Med 1986; 104:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/32\">",
"      Mamus SW, Burton JD, Groat JD, et al. Ibuprofen-associated pure white-cell aplasia. N Engl J Med 1986; 314:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/33\">",
"      Cramer RL, Aboko-Cole VC, Gualtieri RJ. Agranulocytosis associated with etodolac. Ann Pharmacother 1994; 28:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/34\">",
"      Muroi K, Ito M, Sasaki R, et al. Treatment of drug-induced agranulocytosis with granulocyte-colony stimulating factor. Lancet 1989; 2:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/35\">",
"      Colomina P, Garcia S. Agranulocytosis caused by diclofenac. DICP 1989; 23:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/36\">",
"      Garc&iacute;a S, Belda J, Linares M, et al. Piroxicam-induced agranulocytosis. Drug Intell Clin Pharm 1988; 22:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/37\">",
"      D'Arcy PF. Risks of agranulocytosis and aplastic anemia with analgesic use. Int Pharm J 1987; 1:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/38\">",
"      Strom BL, Carson JL, Schinnar R, et al. Nonsteroidal anti-inflammatory drugs and neutropenia. Arch Intern Med 1993; 153:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/39\">",
"      Rouveix B, Coulombel L, Aymard JP, et al. Amodiaquine-induced immune agranulocytosis. Br J Haematol 1989; 71:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/40\">",
"      Clarke JB, Neftel K, Kitteringham NR, Park BK. Detection of antidrug IgG antibodies in patients with adverse drug reactions to amodiaquine. Int Arch Allergy Appl Immunol 1991; 95:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/41\">",
"      Soff GA, Kadin ME. Tocainide-induced reversible agranulocytosis and anemia. Arch Intern Med 1987; 147:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/42\">",
"      Volosin K, Greenberg RM, Greenspon AJ. Tocainide associated agranulocytosis. Am Heart J 1985; 109:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/43\">",
"      Ellrodt AG, Murata GH, Riedinger MS, et al. Severe neutropenia associated with sustained-release procainamide. Ann Intern Med 1984; 100:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/44\">",
"      Samlowski WE, Frame RN, Logue GL. Flecanide-induced immune neutropenia. Documentation of a hapten-mediated mechanism of cell destruction. Arch Intern Med 1987; 147:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/45\">",
"      Vincent MD, Clink HM, Coombes RC, et al. Aminoglutethimide (with hydrocortisone) induced agranulocytosis in primary breast cancer. Br Med J (Clin Res Ed) 1985; 291:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/46\">",
"      Caldwell G, Bradbury A, Toft AD. Aminoglutethimide induced agranulocytosis in breast cancer. Br Med J (Clin Res Ed) 1985; 291:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/47\">",
"      H&ouml;rnsten P, Keisu M, Wiholm BE. The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988. Arch Dermatol 1990; 126:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/48\">",
"      Piga A, Roggero S, Salussolia I, et al. Deferiprone. Ann N Y Acad Sci 2010; 1202:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/49\">",
"      Cohen AR, Galanello R, Piga A, et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003; 102:1583.",
"     </a>",
"    </li>",
"    <li>",
"     www.adverse-effects.com/agranulocytosis/case_reports.html (Accessed on October 05, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/51\">",
"      Ib&aacute;&ntilde;ez L, Vidal X, Ballar&iacute;n E, Laporte JR. Population-based drug-induced agranulocytosis. Arch Intern Med 2005; 165:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/52\">",
"      Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med 1997; 337:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/53\">",
"      Gardner I, Zahid N, MacCrimmon D, Uetrecht JP. A comparison of the oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leukocytes. Mol Pharmacol 1998; 53:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/54\">",
"      Naumann R, Felber W, Heilemann H, Reuster T. Olanzapine-induced agranulocytosis. Lancet 1999; 354:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/55\">",
"      Benedetti F, Cavallaro R, Smeraldi E. Olanzapine-induced neutropenia after clozapine-induced neutropenia. Lancet 1999; 354:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/56\">",
"      Berdoukas V, Farmaki K, Carson S, et al. Treating thalassemia major-related iron overload: the role of deferiprone. J Blood Med 2012; 3:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/57\">",
"      Galanello R, Campus S. Deferiprone chelation therapy for thalassemia major. Acta Haematol 2009; 122:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/58\">",
"      Henter JI, Karl&eacute;n J. Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia. Blood 2007; 109:5157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/59\">",
"      Masera N, Tavecchia L, Longoni DV, et al. Agranulocytosis due to deferiprone: a case report with cytomorphological and functional bone marrow examination. Blood Transfus 2011; 9:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/60\">",
"      Guffy MM, Goeken NE, Burns CP. Granulocytotoxic antibodies in a patient with propylthiouracil-induced agranulocytosis. Arch Intern Med 1984; 144:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/61\">",
"      Shiran A, Shechner C, Dickstein G. Propylthiouracil-induced agranulocytosis in four patients previously treated with the drug. JAMA 1991; 266:3129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/62\">",
"      Tajiri J, Noguchi S, Murakami T, Murakami N. Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring. Arch Intern Med 1990; 150:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/63\">",
"      Fincher ME, Fariss BL, Plymate SR, et al. Agranulocytosis and a small dose of methimazole. Ann Intern Med 1984; 101:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/64\">",
"      Cooper DS, Goldminz D, Levin AA, et al. Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. Ann Intern Med 1983; 98:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/65\">",
"      Tamai H, Takaichi Y, Morita T, et al. Methimazole-induced agranulocytosis in Japanese patients with Graves' disease. Clin Endocrinol (Oxf) 1989; 30:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/66\">",
"      Keisu M, Ekman E. Sulfasalazine associated agranulocytosis in Sweden 1972-1989. Clinical features, and estimation of its incidence. Eur J Clin Pharmacol 1992; 43:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/67\">",
"      Jick H, Myers MW, Dean AD. The risk of sulfasalazine- and mesalazine-associated blood disorders. Pharmacotherapy 1995; 15:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/68\">",
"      Farr M, Scott DG, Bacon PA. Side effect profile of 200 patients with inflammatory arthritides treated with sulphasalazine. Drugs 1986; 32 Suppl 1:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/69\">",
"      Amos RS, Pullar T, Bax DE, et al. Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years. Br Med J (Clin Res Ed) 1986; 293:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/70\">",
"      Keisu M, Wiholm BE, Palmblad J. Trimethoprim-sulphamethoxazole-associated blood dyscrasias. Ten years' experience of the Swedish spontaneous reporting system. J Intern Med 1990; 228:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/71\">",
"      Andr&egrave;s E, Maloisel F. Antibiotic-induced agranulocytosis: a monocentric study of 21 cases. Arch Intern Med 2001; 161:2619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/72\">",
"      Haushofer A, Halbmayer WM, Prachar H. Neutropenia with ticlopidine plus aspirin. Lancet 1997; 349:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/73\">",
"      Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/74\">",
"      Hass WK, Easton JD, Adams HP Jr, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989; 321:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/75\">",
"      Carlson JA, Maesner JE. Fatal neutropenia and thrombocytopenia associated with ticlopidine. Ann Pharmacother 1994; 28:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/76\">",
"      Szto GY, Linnemeier TJ, Ball MW. Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting. Am J Cardiol 1999; 83:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/77\">",
"      Bennett CL, Davidson CJ, Raisch DW, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch Intern Med 1999; 159:2524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/78\">",
"      Kao TW, Hung CC, Chen YC, Tien HF. Ticlopidine-induced aplastic anemia: report of three Chinese patients and review of the literature. Acta Haematol 1997; 98:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/79\">",
"      Tesfa D, Ajeganova S, H&auml;gglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum 2011; 63:2209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/80\">",
"      Rozman S, Sonc M, Novakovic BJ. Late-onset neutropenia following primary treatment of diffuse large B-cell lymphoma with rituximab-containing therapy. Leuk Lymphoma 2012; 53:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/81\">",
"      Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore) 2010; 89:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/82\">",
"      Grant C, Wilson WH, Dunleavy K. Neutropenia associated with rituximab therapy. Curr Opin Hematol 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/83\">",
"      Cattaneo C, Spedini P, Casari S, et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma 2006; 47:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/84\">",
"      Li SC, Chen YC, Evens AM, et al. Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor Fc&gamma;RIIIa 158(V/F) polymorphism. Am J Hematol 2010; 85:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/85\">",
"      Weng WK, Negrin RS, Lavori P, Horning SJ. Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma. J Clin Oncol 2010; 28:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/86\">",
"      Keane C, Nourse JP, Crooks P, et al. Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma. Intern Med J 2012; 42:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/87\">",
"      Hincks I, Woodcock BE, Thachil J. Is rituximab-induced late-onset neutropenia a good prognostic indicator in lymphoproliferatve disorders? Br J Haematol 2011; 153:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/88\">",
"      Lee KC, Ladizinski B, Federman DG. Complications associated with use of levamisole-contaminated cocaine: an emerging public health challenge. Mayo Clin Proc 2012; 87:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/89\">",
"      Tesfa D, Keisu M, Palmblad J. Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management. Am J Hematol 2009; 84:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/90\">",
"      Uetrecht JP. Current trends in drug-induced autoimmunity. Toxicology 1997; 119:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/91\">",
"      Uetrecht JP. Myeloperoxidase as a generator of drug free radicals. Biochem Soc Symp 1995; 61:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/92\">",
"      Uetrecht JP. Idiosyncratic drug reactions: possible role of reactive metabolites generated by leukocytes. Pharm Res 1989; 6:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/93\">",
"      Ju C, Uetrecht JP. Oxidation of a metabolite of indomethacin (Desmethyldeschlorobenzoylindomethacin) to reactive intermediates by activated neutrophils, hypochlorous acid, and the myeloperoxidase system. Drug Metab Dispos 1998; 26:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/94\">",
"      Christie DJ. Specificity of drug-induced immune cytopenias. Transfus Med Rev 1993; 7:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/95\">",
"      Dorr VJ, Cook J. Agranulocytosis and near fatal sepsis due to 'Mexican aspirin' (dipyrone). South Med J 1996; 89:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/96\">",
"      Edwards JE, McQuay HJ. Dipyrone and agranulocytosis: what is the risk? Lancet 2002; 360:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/97\">",
"      Pisciotta AV. Drug-induced agranulocytosis. Peripheral destruction of polymorphonuclear leukocytes and their marrow precursors. Blood Rev 1990; 4:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/98\">",
"      Uetrecht J, Zahid N, Tehim A, et al. Structural features associated with reactive metabolite formation in clozapine analogues. Chem Biol Interact 1997; 104:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/99\">",
"      Gerson SL, Meltzer H. Mechanisms of clozapine-induced agranulocytosis. Drug Saf 1992; 7 Suppl 1:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/100\">",
"      Uetrecht J, Zahid N, Shear NH, Biggar WD. Metabolism of dapsone to a hydroxylamine by human neutrophils and mononuclear cells. J Pharmacol Exp Ther 1988; 245:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/101\">",
"      Parent-Massin DM, Sens&eacute;b&eacute; L, L&eacute;glise MC, et al. Relevance of in vitro studies of drug-induced agranulocytosis. Report of 14 cases. Drug Saf 1993; 9:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/102\">",
"      Jacobson IM, Kelsey PB, Blyden GT, et al. Sulfasalazine-induced agranulocytosis. Am J Gastroenterol 1985; 80:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/103\">",
"      Black E, Lau TT, Ensom MH. Vancomycin-induced neutropenia: is it dose- or duration-related? Ann Pharmacother 2011; 45:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/104\">",
"      Copolov DL, Bell WR, Benson WJ, et al. Clozapine treatment in Australia: a review of haematological monitoring. Med J Aust 1998; 168:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/105\">",
"      Heit W, Heimpel H, Fischer A, Frickhofen N. Drug-induced agranulocytosis: evidence for the commitment of bone marrow haematopoiesis. Scand J Haematol 1985; 35:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/106\">",
"      Meyer-Gessner M, Benker G, Lederbogen S, et al. Antithyroid drug-induced agranulocytosis: clinical experience with ten patients treated at one institution and review of the literature. J Endocrinol Invest 1994; 17:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/107\">",
"      Juli&aacute; A, Olona M, Bueno J, et al. Drug-induced agranulocytosis: prognostic factors in a series of 168 episodes. Br J Haematol 1991; 79:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/108\">",
"      G&oacute;ra-Tybor J, Krykowski E, Robak T. Treatment of drug-induced agranulocytosis with colony stimulating factors (G-CSF or GM-CSF). Arch Immunol Ther Exp (Warsz) 1996; 44:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/109\">",
"      Tajiri J, Noguchi S, Murakami N. Usefulness of granulocyte count measurement four hours after injection of granulocyte colony-stimulating factor for detecting recovery from antithyroid drug-induced granulocytopenia. Thyroid 1997; 7:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/110\">",
"      Wickramanayake PD, Scheid C, Josting A, et al. Use of granulocyte colony-stimulating factor (filgrastim) in the treatment of non-cytotoxic drug-induced agranulocytosis. Eur J Med Res 1995; 1:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/111\">",
"      Balkin MS, Buchholtz M, Ortiz J, Green AJ. Propylthiouracil (PTU)-induced agranulocytosis treated with recombinant human granulocyte colony-stimulating factor (G-CSF). Thyroid 1993; 3:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/112\">",
"      Andr&egrave;s E, Kurtz JE, Martin-Hunyadi C, et al. Nonchemotherapy drug-induced agranulocytosis in elderly patients: the effects of granulocyte colony-stimulating factor. Am J Med 2002; 112:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/113\">",
"      Mossad SB. Agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 2008; 148:320; author reply 320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/21/21850/abstract/114\">",
"      Fukata S, Kuma K, Sugawara M. Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocytosis: a prospective study. Thyroid 1999; 9:29.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8374 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-DB525E7F52-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_21_21850=[""].join("\n");
var outline_f21_21_21850=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      AGRANULOCYTOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H694262921\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DRUG-INDUCED NEUTROPENIA/AGRANULOCYTOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Implicated agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Psychotropic drugs and anticonvulsants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Clozapine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Olanzapine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1033710\">",
"      Deferiprone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Thionamides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Sulfasalazine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Ticlopidine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7617817\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cocaine and heroin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Immune-mediated destruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Direct and indirect toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PREVENTION AND SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Clozapine screening programs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1033971\">",
"      Deferiprone screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Thionamides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Withdrawal of the offending agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Treatment of associated infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Granulocyte colony-stimulating factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Diagnosis and differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Initial studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Cessation of offending drug",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Colony-stimulating factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1033656\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/8374\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8374|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/19/10555\" title=\"table 1\">",
"      Neutropenia and infectious risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/4/40013\" title=\"table 2\">",
"      Drugs and agranulocytosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?12/1/12305?source=related_link\" title=\"calculator 1\">",
"      Calculator: Absolute neutrophil count",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=related_link\">",
"      Congenital neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6793?source=related_link\">",
"      Guidelines for prescribing clozapine in schizophrenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42520?source=related_link\">",
"      Immune neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10473?source=related_link\">",
"      Infectious causes of neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24614?source=related_link\">",
"      Laboratory evaluation of neutropenia and neutrophil dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=related_link\">",
"      Overview of neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=related_link\">",
"      Overview of neutropenic fever syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/59/25521?source=related_link\">",
"      Patient information: Neutropenia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41303?source=related_link\">",
"      Pharmacology and toxicity of thionamides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=related_link\">",
"      Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/27/2490?source=related_link\">",
"      Sulfasalazine in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=related_link\">",
"      Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_21_21851="Causes of organizing pneumonia";
var content_f21_21_21851=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of organizing pneumonia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Cryptogenic organizing pneumonia (previously called bronchiolitis obliterans organizing pneumonia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Organizing diffuse alveolar damage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diffuse alveolar hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Amiodarone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cocaine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Infections (organizing)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mycoplasma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Viral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pneumocystis jirovecii (carinii)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bacterial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Connective tissue diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypersensitivity pneumonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic pulmonary fibrosis (minor scattered foci)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aspiration",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_21_21851=[""].join("\n");
var outline_f21_21_21851=null;
var title_f21_21_21852="Rapid screen for confusion in adults";
var content_f21_21_21852=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F70343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F70343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rapid screen for confusion in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Item",
"       </td>",
"       <td class=\"subtitle1\">",
"        Scoring",
"       </td>",
"       <td class=\"subtitle1\">",
"        Weight",
"       </td>",
"       <td class=\"subtitle1\">",
"        Score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        What year is it now?",
"       </td>",
"       <td>",
"        <p>",
"         0 or 1",
"        </p>",
"        <p>",
"         (Score 1 if correct, 0 if incorrect)",
"        </p>",
"       </td>",
"       <td>",
"        x2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        What month is it?",
"       </td>",
"       <td>",
"        <p>",
"         0 or 1",
"        </p>",
"        <p>",
"         (Score 1 if correct, 0 if incorrect)",
"        </p>",
"       </td>",
"       <td>",
"        x2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Repeat phrase and remember: \"John Brown, 42 Market Street, New York\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        About what time is it? (answer correct if within one hour)",
"       </td>",
"       <td>",
"        <p>",
"         0 or 1",
"        </p>",
"        <p>",
"         (Score 1 if correct, 0 if incorrect)",
"        </p>",
"       </td>",
"       <td>",
"        x2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Count backwards from 20 to 1",
"       </td>",
"       <td>",
"        <p>",
"         0, 1, or 2",
"        </p>",
"        <p>",
"         (Score 2 if correct, 1 if 1 error, and 0 if 2 or more errors)",
"        </p>",
"       </td>",
"       <td>",
"        x1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Say the months in reverse",
"       </td>",
"       <td>",
"        <p>",
"         0, 1, or 2",
"        </p>",
"        <p>",
"         (Score 2 if correct, 1 if 1 error, and 0 if 2 or more errors)",
"        </p>",
"       </td>",
"       <td>",
"        x1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Repeat memory phrase",
"       </td>",
"       <td>",
"        <p>",
"         0, 1, 2, 3, 4, 5",
"        </p>",
"        <p>",
"         (Score 5 if correct; deduct 1 for each miss)",
"        </p>",
"       </td>",
"       <td>",
"        x1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\" colspan=\"4\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        <strong>",
"         Final score is sum of the total; score less than 15 suggests the presence of altered cognition and need for further assessment.",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_21_21852=[""].join("\n");
var outline_f21_21_21852=null;
var title_f21_21_21853="Reasons for adolescent suicide";
var content_f21_21_21853=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69888&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69888&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Percentage of persons aged &le;17 years who reported reasons for attempting suicide*, by age and sex - Oregon, 1990-1993",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Reason",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Sex",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Age",
"group, years",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Total&bull;,",
"n=2231",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Male n=436",
"       </td>",
"       <td class=\"subtitle2\">",
"        Female, n=1749",
"       </td>",
"       <td class=\"subtitle2\">",
"        &lt;12, n=1001",
"       </td>",
"       <td class=\"subtitle2\">",
"        13-14, n=640",
"       </td>",
"       <td class=\"subtitle2\">",
"        15-17, n=1490",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Family discord",
"       </td>",
"       <td>",
"        53.9",
"       </td>",
"       <td>",
"        60.8",
"       </td>",
"       <td>",
"        73.0",
"       </td>",
"       <td>",
"        65.0",
"       </td>",
"       <td>",
"        56.1",
"       </td>",
"       <td>",
"        59.4&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Argument with boyfriend/girlfriend",
"       </td>",
"       <td>",
"        31.0",
"       </td>",
"       <td>",
"        33.0",
"       </td>",
"       <td>",
"        8.0",
"       </td>",
"       <td>",
"        23.1",
"       </td>",
"       <td>",
"        38.3",
"       </td>",
"       <td>",
"        32.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        School-related problems",
"       </td>",
"       <td>",
"        27.5",
"       </td>",
"       <td>",
"        21.9",
"       </td>",
"       <td>",
"        32.0",
"       </td>",
"       <td>",
"        26.9",
"       </td>",
"       <td>",
"        20.7",
"       </td>",
"       <td>",
"        23.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rape/sexual abuse",
"       </td>",
"       <td>",
"        4.1",
"       </td>",
"       <td>",
"        11.2",
"       </td>",
"       <td>",
"        7.0",
"       </td>",
"       <td>",
"        13.0",
"       </td>",
"       <td>",
"        8.7",
"       </td>",
"       <td>",
"        9.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peer pressure/conflict",
"       </td>",
"       <td>",
"        7.3",
"       </td>",
"       <td>",
"        8.2",
"       </td>",
"       <td>",
"        10.0",
"       </td>",
"       <td>",
"        10.0",
"       </td>",
"       <td>",
"        7.0",
"       </td>",
"       <td>",
"        8.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Substance abuse",
"       </td>",
"       <td>",
"        15.1",
"       </td>",
"       <td>",
"        6.0",
"       </td>",
"       <td>",
"        3.0",
"       </td>",
"       <td>",
"        5.9",
"       </td>",
"       <td>",
"        8.9",
"       </td>",
"       <td>",
"        7.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Move or new school",
"       </td>",
"       <td>",
"        5.7",
"       </td>",
"       <td>",
"        6.0",
"       </td>",
"       <td>",
"        7.0",
"       </td>",
"       <td>",
"        8.6",
"       </td>",
"       <td>",
"        4.8",
"       </td>",
"       <td>",
"        6.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Legal system encounters",
"       </td>",
"       <td>",
"        14.0",
"       </td>",
"       <td>",
"        2.6",
"       </td>",
"       <td>",
"        4.0",
"       </td>",
"       <td>",
"        4.7",
"       </td>",
"       <td>",
"        5.0",
"       </td>",
"       <td>",
"        4.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Death of family member/friend",
"       </td>",
"       <td>",
"        4.8",
"       </td>",
"       <td>",
"        4.5",
"       </td>",
"       <td>",
"        6.0",
"       </td>",
"       <td>",
"        4.2",
"       </td>",
"       <td>",
"        4.6",
"       </td>",
"       <td>",
"        4.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Physical abuse",
"       </td>",
"       <td>",
"        3.7",
"       </td>",
"       <td>",
"        3.3",
"       </td>",
"       <td>",
"        5.0",
"       </td>",
"       <td>",
"        2.7",
"       </td>",
"       <td>",
"        3.6",
"       </td>",
"       <td>",
"        3.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suicide of friend/relative&Delta;",
"       </td>",
"       <td>",
"        4.4",
"       </td>",
"       <td>",
"        3.1",
"       </td>",
"       <td>",
"        2.0",
"       </td>",
"       <td>",
"        4.8",
"       </td>",
"       <td>",
"        2.8",
"       </td>",
"       <td>",
"        3.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnancy",
"       </td>",
"       <td>",
"        0.9",
"       </td>",
"       <td>",
"        2.7",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        1.6",
"       </td>",
"       <td>",
"        2.9",
"       </td>",
"       <td>",
"        2.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other reasons",
"       </td>",
"       <td>",
"        15.8",
"       </td>",
"       <td>",
"        14.1",
"       </td>",
"       <td>",
"        9.0",
"       </td>",
"       <td>",
"        13.9",
"       </td>",
"       <td>",
"        15.0",
"       </td>",
"       <td>",
"        14.4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Categories are not mutually exclusive because more than one reason may have been reported.",
"     <br>",
"      &bull; Includes one person for whom sex and age data were missing.",
"      <br>",
"       &Delta; Includes suicide attempts.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Source: Oregon Adolescent Suicide Attempt Data System. 1990 was the first full year the reason for the attempt was collected. Only attempts for which reasons were given are included.",
"     <br>",
"      Adapted from MMWR Morb Mortal Wkly Rep 1995; 44:312.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_21_21853=[""].join("\n");
var outline_f21_21_21853=null;
var title_f21_21_21854="Combination chemotherapy STS";
var content_f21_21_21854=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F80881&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F80881&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Commonly used chemotherapy combinations for patients with soft tissue sarcoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Regimen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose (total per cycle)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Schedule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        AI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        LeCesne A; 2000",
"       </td>",
"       <td>",
"        Doxorubicin",
"       </td>",
"       <td>",
"        50 or 75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        day 1 (50 to 75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        )",
"       </td>",
"       <td rowspan=\"3\">",
"        Every 3 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ifosfamide*",
"       </td>",
"       <td>",
"        5 g/m",
"        <sup>",
"         2",
"        </sup>",
"        over 24 hours, day 1 (5 g/m",
"        <sup>",
"         2",
"        </sup>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mesna",
"       </td>",
"       <td>",
"        2.5 g/m",
"        <sup>",
"         2",
"        </sup>",
"        mixed with ifosfamide IV over 24 hours; 1.25 g/m",
"        <sup>",
"         2",
"        </sup>",
"        IV over 12 hours after ifosfamide",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Worden F; 2005",
"       </td>",
"       <td>",
"        Doxorubicin",
"       </td>",
"       <td>",
"        20 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        days 1, 2, 3 (60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        )",
"       </td>",
"       <td rowspan=\"3\">",
"        Every 3 weeks, G-CSF",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ifosfamide*",
"       </td>",
"       <td>",
"        1.5 g/m",
"        <sup>",
"         2",
"        </sup>",
"        over 2 hours, days 1 through 4 (6 g/m",
"        <sup>",
"         2",
"        </sup>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mesna",
"       </td>",
"       <td>",
"        225 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV over 1 hour before ifosfamide, 4 and 8 hours after ifosfamide; G-CSF 5 mcg/kg per day, once daily for 10 days, start on day 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Patel S; 1998",
"       </td>",
"       <td>",
"        Doxorubicin",
"       </td>",
"       <td>",
"        25 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        over 24 hours, days 1, 2, 3 (75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        )",
"       </td>",
"       <td rowspan=\"3\">",
"        Every 3 weeks, G-CSF",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ifosfamide*",
"       </td>",
"       <td>",
"        2 g/m",
"        <sup>",
"         2",
"        </sup>",
"        over 2 hours, days 1 through 5 (10 g/m",
"        <sup>",
"         2",
"        </sup>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mesna",
"       </td>",
"       <td>",
"        400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        with first dose ifosfamide, then start 1200 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        over 24 hours per day, for 5 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Epirubicin/ifosfamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Palumbo R; 1999",
"       </td>",
"       <td>",
"        Epirubicin",
"       </td>",
"       <td>",
"        55 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        start IV bolus, days 1, 2 (110 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        )",
"       </td>",
"       <td rowspan=\"3\">",
"        Every 3 weeks, G-CSF",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ifosfamide*",
"       </td>",
"       <td>",
"        2.5 g/m",
"        <sup>",
"         2",
"        </sup>",
"        over 24 hours, days 1 through 4 (10 g/m",
"        <sup>",
"         2",
"        </sup>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mesna",
"       </td>",
"       <td>",
"        2.5 g/m",
"        <sup>",
"         2",
"        </sup>",
"        over 24 hours, days 1 through 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        AD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Antman K; 1993",
"       </td>",
"       <td>",
"        Doxorubicin",
"       </td>",
"       <td>",
"        15 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        over 24 hours, days 1 through 4 (60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        )",
"       </td>",
"       <td rowspan=\"2\">",
"        Every 3 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dacarbazine",
"       </td>",
"       <td>",
"        250 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        over 24 hours, days 1 through 4 (1000 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        MAID",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"4\">",
"        Antman K; 1993, 1998",
"       </td>",
"       <td>",
"        Doxorubicin",
"       </td>",
"       <td>",
"        15 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        over 24 hours, days 1 through 4",
"       </td>",
"       <td rowspan=\"4\">",
"        Every 3 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ifosfamide*",
"       </td>",
"       <td>",
"        2 g/m",
"        <sup>",
"         2",
"        </sup>",
"        over 24 hours, days 1 through 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dacarbazine",
"       </td>",
"       <td>",
"        250 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        over 24 hours, days 1 through 4 (mix with doxorubicin)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mesna",
"       </td>",
"       <td>",
"        2.5 g/m",
"        <sup>",
"         2",
"        </sup>",
"        over 24 hours, days 1 through 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"4\">",
"        DeLaney T; 2003",
"       </td>",
"       <td>",
"        Doxorubicin",
"       </td>",
"       <td>",
"        20 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        over 24 hours, days 1 through 3",
"       </td>",
"       <td rowspan=\"4\">",
"        Every 3 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ifosfamide*",
"       </td>",
"       <td>",
"        2 g/m",
"        <sup>",
"         2",
"        </sup>",
"        over 24 hours, days 1 through 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dacarbazine",
"       </td>",
"       <td>",
"        250 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        over 24 hours, days 1 through 4 (mix with doxorubicin)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mesna",
"       </td>",
"       <td>",
"        2.5 g/m",
"        <sup>",
"         2",
"        </sup>",
"        over 24 hours, days 1 through 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Gemcitabine/docetaxel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Leu K; 2004",
"       </td>",
"       <td>",
"        Gemcitabine",
"       </td>",
"       <td>",
"        675 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        days 1 and 8",
"       </td>",
"       <td rowspan=\"2\">",
"        Every 3 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Docetaxel",
"       </td>",
"       <td>",
"        100 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        day 8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Hensley M; 2002",
"       </td>",
"       <td>",
"        Gemcitabine",
"       </td>",
"       <td>",
"        900 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        days 1, 8 (675 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        days 1 and 8",
"        <sup>",
"         &Delta;",
"        </sup>",
"        )",
"       </td>",
"       <td rowspan=\"2\">",
"        Every 3 weeks, G-CSF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Docetaxel",
"       </td>",
"       <td>",
"        100 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        day 8 (75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        day 8",
"        <sup>",
"         &Delta;",
"        </sup>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Gemcitabine/vinorelbine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Dileo P; 2007",
"       </td>",
"       <td>",
"        Vinorelbine",
"       </td>",
"       <td>",
"        25 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        over 10 minutes, days 1 and 8",
"       </td>",
"       <td rowspan=\"2\">",
"        Every 3 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gemcitabine",
"       </td>",
"       <td>",
"        800 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        over 90 minutes, days 1 and 8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Gemcitabine/dacarbazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Garcia-del Muro X; 2011",
"       </td>",
"       <td>",
"        Gemcitabine",
"       </td>",
"       <td>",
"        1800 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        , given by fixed rate infusion (10 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per minute), day 1",
"       </td>",
"       <td rowspan=\"2\">",
"        Every 2 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dacarbazine",
"       </td>",
"       <td>",
"        500 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        , day 1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     G-CSF: granulocyte colony-stimulating factor.",
"     <br/>",
"     * With Mesna.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     With routine G-CSF support.",
"     <br/>",
"     &Delta; Lower doses (gemcitabine 675 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     , docetaxel 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) administered to previously irradiated patients.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_21_21854=[""].join("\n");
var outline_f21_21_21854=null;
var title_f21_21_21855="Translocation";
var content_f21_21_21855=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F70807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F70807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Translocation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_21_21855=[""].join("\n");
var outline_f21_21_21855=null;
